

Index to Volume 12

The index to Volume 12 is composed of three parts: a subject index, an author index, and an advertising index.

The subject index is made up mainly of terms constructed by *International Pharmaceutical Abstracts*. The IPA index is an alphabetical, open-ended, controlled-vocabulary index that makes use of standardized headings. (The primary index terms for each article are listed routinely in *Clinical Pharmacy* as "index terms" after abstracts.) IPA covers all authored papers and editorials in

Clinical Pharmacy, as well as selected letters and news reports. The subject index also notes all regular columns and, under the respective column headings, the titles of items in the "News," "Therapy Consultation," "Letters," "Editorials," and "Book Reviews" sections. The subject index also contains, under the heading "Correction Notices," the title and issue of publication of items for which corrections were printed, as well as the page numbers on which the corrections appear.

Issue	Pages
January	1-84
February	85-164
March	165-244
April	245-324
May	325-388
June	389-468

Issue	Pages
July	469-548
August	549-628
September	629-708
October	709-788
November	789-868
December	869-948

Subject Index

A

Accetainide; blood levels; fluorescence polarization methods, 49
N-Acetyl-L-tyrosine; excretion; excretion, infants, parenteral nutrition, 606
N-Acetylprocainamide; see **Accetainide**
Acquired immunodeficiency syndrome
 atovaquone; pneumonia therapy, FDA approvals, 175
 didanosine, comparison, zalcitabine; therapy, efficacy, NIAID clinical studies, 391
 stavudine; therapy, parallel track policy, FDA approvals, 7
 unapproved drugs; imports, AIDS buyers' clubs, FDA regulations, 632
 zalcitabine, comparison, didanosine; therapy, efficacy, NIAID clinical studies, 391
Acylovir; chickenpox; rational therapy, AAP recommendations, 175
Addicts; opiates; levomethadyl maintenance, narcotic treatment programs, 797
Administration
 hospital pharmacy; NSAs, DUE criteria, 780
 Food and Drug Administration; accelerated drug approvals, final regulations, 253
Adrenergic agents; see **Sympathomimetic agents**
Adverse reactions; see **Drugs, adverse reactions**
Advertising; industry, pharmaceutical; accelerated drug approvals, FDA regulations, 253
Advertising Index, 84, 164, 244, 324, 388, 468, 548, 628, 708, 788, 868, 935
AIDS; see **Acquired immunodeficiency syndrome**
Age
 patients; effects, mexiletine pharmacokinetics, 768
 pediatrics; N-acetyl-L-tyrosine, excretion, infants, nutrition, 606
Agency for Health Care Policy and Research; grants; pharmacists' role, health care, 474
Agranulocytosis; sargamostim; therapy, sulfasalazine toxicity, 179
Albumin human; effects; serum protein levels, parenteral nutrition, 377
Albumin; replacement solutions; selection, clinical studies, review, 335
Aldesleukin; use; evaluation, criteria, 853
Allergies
 drugs; photosensitivity, review, 580
 temafloxacin hydrochloride; hemolytic anemia, 380
Alprazolam; premenstrual syndrome; therapy, psychological symptoms, 181
Alzheimer's disease; tacrine hydrochloride; therapy, FDA approvals, 873
American Academy of Pediatrics
 acyclovir; chickenpox therapy, AAP recommendations, 175
 chloral hydrate; pediatric use, recommendations, 876

American Journal of Hospital Pharmacy; journals; merging, *Clinical Pharmacy*, 526, 923
American Society of Hospital Pharmacists
 journals; *AJHP*, *Clinical Pharmacy*, merging, 526, 923
 protocols; antimicrobial prophylaxis, colorectal surgery, 399
Amino acids; dietary supplements; athletes, ergogenic effects, 900
Aminoglycosides
 gentamicin; pharmacokinetics, prediction, vancomycin pharmacokinetics, 909
 gentamicin sulfate; body distribution, septic shock, 131; pharmacokinetics, term newborn twins, 615
 tobramycin; pharmacokinetics, prediction, vancomycin pharmacokinetics, 909
 tobramycin sulfate; body distribution, septic shock, 131
Amiodarone
 photosensitivity; toxicity, review, 580
 toxicity; thyroid dysfunction, therapy, 774
Amlodipine besylate; marketing; FDA approvals, 93
Amoxicillin; bismuth and metronidazole; peptic ulcer therapy, *H. pylori*, review, 34
Analgesics and antipyretics
 fentanyl; transdermal pain therapy, 718
 meperidine hydrochloride; patient-controlled analgesia, DUE criteria, 150
 morphine; fentanyl replacement pain therapy, 718
 morphine sulfate; patient-controlled analgesia, DUE criteria, 150
 premenstrual syndrome; therapy, headache, 181
Anaphylaxis; replacement solutions; review, 335
Anemia
 epoetin alfa; therapy, DUE criteria, 925
 temafloxacin hydrochloride; hemolytic, adverse reactions, 380
Anesthetics
 midazolam hydrochloride; follicular fluid levels, in vitro fertilization, 770
 propofol; toxicity, aggressive sex behavior, 449
Anesthetics, local; benzocaine; allergies, photosensitivity, review, 580
Angina pectoris; amlodipine besylate; therapy, FDA approvals, 93
Angiotensin-converting-enzyme inhibitors
 hypertension; systolic, therapy, geriatrics, review, 347
 proteinuria; therapy, nephrotic syndrome, review, 429
Antacids; labeling; nonprescription drugs, FDA regulations, 800
Anthracyclines; toxicity; extravasation, dimethyl sulfoxide therapy, 560
Antiarrhythmic drugs, see **Cardiac drugs**
Antidiarrhea agents; labeling; nonprescription drugs, FDA regulations, 800
Antiemetics; labeling; nonprescription drugs, FDA regulations, 800
Antianemia drugs; epoetin alfa; DUE criteria, 925

Antibiotics
 aztreonam and clindamycin; or metronidazole, colorectal surgery, prophylaxis, 399
 clindamycin and aztreonam; colorectal surgery, prophylaxis, 399
 cystic fibrosis; therapy, review, 657
 shock; septic, therapy, review, 829
 vancomycin; pharmacokinetics, geriatrics, 481; pharmacokinetics, prediction, 909
 vancomycin hydrochloride; dosage, calculations, computers, 126; pharmacokinetics, dosage, hematologic malignancy, 515
Antibodies; monoclonal; graft vs. host disease, prophylaxis, transplantation, 736; septic shock therapy, review, 829
Anticoagulants
 enoxaparin; FDA approvals, 471
 glomerulonephritis; membranoproliferative, therapy, review, 429
 heparin; dosage estimation, pharmacokinetic models, 597; low molecular weight, cerebrovascular disorders therapy, review, 359; myocardial infarction therapy, 197
 heparins; low-molecular-weight vs. unfractionated, thrombophlebitis, 892
 ticlopidine hydrochloride; toxicity, cholestasis, 398
 warfarin; atrial fibrillation, atrial flutter therapy, 721; myocardial infarction therapy, 197
Anticonvulsants
 diazepam; seizures, therapy, ondansetron adverse reactions, 613
 felbamate; marketing, FDA approvals, 713
 phenytoin; unbound, blood levels prediction, equations, 913
 valproic acid; toxicity, pancreatitis, review, 440
Antidepressants
 premenstrual syndrome; therapy, psychological symptoms, 181
 sertraline hydrochloride; interactions, tranylcypromine, serotonergic syndrome, 222
 tranylcypromine sulfate; interactions, sertraline, serotonergic syndrome, 222
Antiemetics; ondansetron hydrochloride; adverse reactions, seizures, 613
Antifungals; itraconazole; FDA approvals, 6
Antihistamines; loratadine; FDA approvals, 474
Anti-infective agents
 atovaquone; pneumonia therapy, FDA approvals, 175
 metronidazole; and aztreonam, colorectal surgery, prophylaxis, 399; peptic ulcers, *H. pylori*, combined therapy, review, 34; diarrhea, therapy, cefixime toxicity, 881
 pentamidine; toxicity, pancreatitis, review, 440
 peritonitis; therapy, effects, α -acid glycoprotein concentrations, 602
Anti-inflammatory agents
 methotrexate; asthma therapy, overview, 762
 nonsteroidal; DUE criteria, 780; polymyalgia rheu-

- matia therapy, review, 571; proteinuria therapy, nephrotic syndrome, review, 429
 sulindac; toxicity, pancreatitis, review, 440
Antileptic agents; nephrotic syndrome; complications, therapy, review, 429
Antineoplastic agents; lithium; DUE criteria, 617
Antineoplastic agents
 aldesleukin; DUE criteria, 853
 asparaginase; toxicity, pancreatitis, review, 440
 cladribine; FDA approvals, 391; leukemia therapy, review, 805
 finasteride; prostatic hypertrophy therapy, review, 15
 leucovorin calcium, comparison, leucovorin calcium; equivalency, i.v. vs. oral, availability, 293
 leucovorin calcium, comparison, leucovorin calcium; equivalency, i.v. vs. oral, availability, 293
 mercaptopurine; toxicity, pancreatitis, review, 440
 nephrotic syndrome; therapy, review, 429
 paclitaxel; refractory ovarian neoplasms therapy, review, 401
 teniposide; FDA approvals, 6
 toxicity; anemia, epoetin alfa therapy, DUE criteria, 925
Antithymocyte globulin; graft vs. host disease; prophylaxis, bone marrow transplantation, 736
Antithyroid drugs
 hyperthyroidism; therapy, 774
 propylthiouracil; hyperthyroidism therapy, 774
Antituberculars; resistance; *M. tuberculosis*, health professions, surveillance programs, 167
Antivirals
 acyclovir; chickenpox therapy, AAP recommendations, 175
 didanosine; toxicity, pancreatitis, review, 440
 didanosine, comparison, zalcitabine; AIDS therapy, efficacy, NIAID clinical studies, 391
 ribavirin; bronchiolitis therapy, pediatrics, review, 95
 stavudine; AIDS therapy, parallel track policy, FDA approvals, 7
 zalcitabine, comparison, didanosine; AIDS therapy, efficacy, NIAID clinical studies, 391
Anxiolytics, sedatives and hypnotics
 chloral hydrate; pediatric use, AAP recommendations, 876
 labeling; nonprescription drugs, FDA regulations, 800
 zolpidem tartrate; insomnia therapy, review, 814
Arrhythmia; sotalol hydrochloride; therapy, review, 883; ventricular, therapy, FDA approvals, 176
Arteritis; relationship; giant cell, polymyalgia rheumatica therapy, 571
Arthritis; anti-inflammatory agents; nonsteroidal, therapy, DUE criteria, 780
Asparaginase; toxicity; pancreatitis, review, 440
Aspergillosis; prednisone; allergic bronchopulmonary, therapy, review, 24
Asthma; methotrexate; therapy, overview, 762
Athletes; dietary supplements; ergogenic effects, 900
Atovaquone
 marketing; FDA approvals, 175
 pneumonia; *P. carinii*, therapy, review, 563
Atrial fibrillation; therapy; review, 721
Atrial flutter; therapy; review, 721
Availability, drugs, see Drugs, availability
Azathioprine; toxicity; pancreatitis, review, 440
Aztreonam; and clindamycin or metronidazole; colorectal surgery, prophylaxis, ASHP protocols, 399

B

- Bacterial infections;** anti-infective agents; colorectal surgery, prophylaxis, ASHP protocols, 399
BCG vaccines; immunization; tuberculosis, health professions, surveillance programs, 167
Benzocaine; photosensitivity; adverse reactions, review, 580
Benzodiazepine antagonists; flumazenil; DUE criteria, 536; overdose, therapy, review, 641; rational therapy, overdose, overview, 691; respiratory depression therapy, benzodiazepine toxicity, 483
Benzodiazepines
 overdose; toxicity, flumazenil therapy, DUE criteria, 536
 toxicity; overdose, flumazenil therapy, overview, 691; overdose, flumazenil therapy, review, 641; respiratory depression, flumazenil therapy, 483
Bezoars; nifedipine; toxicity, sustained-action tablets, 849
Binding
 phenytoin; proteins, unbound levels prediction, 913
 quinidine; plasma, effects, ultrafiltration, 917
Bioavailability, see Drugs, availability
Biotechnology; shock; septic, therapy, review, 829

- Bipolar disorder;** lithium; therapy, DUE criteria, 617
Bismuth; ulcers; peptic, combined therapy, *H. pylori*, review, 34
Blastomycosis; itraconazole; therapy, FDA approvals, 6
Blood levels
 acecainide; fluorescence polarization methods, 49
 N-acetyl-L-tyrosine; excretion, infants, parenteral nutrition, 606
 α -acid glycoproteins; and dialysate, effects, peritonitis, 602
 clonidine hydrochloride; infant, maternal consumption, lactation, 178
 gentamicin; pharmacokinetics, term newborn twins, 615
 lidocaine hydrochloride; monitoring, pharmacists' role, 527
 N-5-methyltetrahydrofolate; leucovorin-leucovorin generic equivalency, 293
 midazolam hydrochloride; follicular fluid, in vitro fertilization, 770
 phenytoin; prediction, equations, unbound concentration, 913
 procainamide; fluorescence polarization methods, 49
 quinidine; binding, effects, ultrafiltration, 917; fluorescence polarization vs. EMIT, 49
 tetrahydrofolic acid; leucovorin-leucovorin generic equivalency, 293
 vancomycin; dosage calculations, computers, 126; pharmacokinetics, geriatrics, 481
Blood; resuscitation; clinical studies, review, 335
Bone neoplasms; strontium chloride Sr 89; pain therapy, FDA approvals, 632
Book Reviews, 76, 240, 323, 387, 467, 627, 704, 787, 864, 933
Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, Third Edition, 323
Cancer: Principles and Practice of Oncology, 4th Edition, 864
The Chemotherapy Source Book, 240
Clinical Epidemiology: A Basic Science for Clinical Medicine, Second Edition, 866
Clinical Pharmacokinetics Pocket Reference, 933
Clinical Pharmacology: Basic Principles in Therapeutics, Third Edition, 76
Clinical Pharmacy and Therapeutics, Fifth Edition, 704
Drugs in Anaesthetic Practice, Seventh Edition, 241
Drug Susceptibility in the Chemotherapy of Mycobacterial Infections, 82
Essentials of Basic Science: Pharmacology, 704
Geriatric Nutrition: The Health Professional's Handbook, 933
Handbook of Cancer Chemotherapy, Third Edition, 241
Handbook of Clinical Drug Data, Seventh Edition, 706
Handbook of Medical Toxicology, 627
Handbook of Psychotropic Drugs, 242
Management of HIV Infection in Infants and Children, 787
Martindale: The Extra Pharmacopoeia, 30th Edition, 934
Patient Recruitment in Clinical Trials, 387
Progress in Basic and Clinical Pharmacology, Vol. 9: Effects of Drugs on Human Functioning, 867
Tardive Dyskinesia, 467
Textbook of Clinical Neuropharmacology and Therapeutics, Second Edition, 707
Books Received, 84, 164, 324, 388, 468, 548, 627, 707, 787, 867, 935
Boots Pharmaceuticals; flosequinan; product withdrawal, toxicity, 713
Bromocriptine; premenstrual syndrome; therapy, mastodynia, 181
Bronchiolitis; therapy; pediatrics, review, 95

C

- Calcium antagonists**
 atrial fibrillation; therapy, and atrial flutter, 721
 felodipine; hypertension therapy, review, 261
 hypertension; systolic, therapy, geriatrics, review, 347
 isradipine; hypertension therapy, review, 261
Calcium regulators
 gallium nitrate; hypercalcemia therapy, malignancy-induced, review, 117
 pamidronate disodium; hypercalcemia therapy, malignancy-induced, review, 117
Calculations
 aminoglycosides; pharmacokinetics, prediction, 909
 creatinine; clearance, estimation, gynecologic neoplasms, 685
 phenytoin; dosage, unbound, blood levels prediction, 913
 vancomycin; dosage, computer programs, 126
Cancer, see Antineoplastic agents
Cancer drugs, see Antineoplastic agents
Carbohydrates; nutrition; support, respiratory tract diseases, 276
Carcinogenicity; chloral hydrate; toxicity, lack, 876
Cardiac drugs
 amiodarone; photosensitivity, toxicity, review, 580; toxicity, thyroid dysfunction, therapy, 774
 amlodipine besylate; FDA approvals, 93
 antiarrhythmic agents; atrial fibrillation, atrial flutter therapy, 721
 digoxin; atrial fibrillation, atrial flutter therapy, 721
 flosequinan; high dose, toxicity, clinical studies, 474; product withdrawal, toxicity, 713
 isosorbide dinitrate; systolic hypertension therapy, geriatrics, review, 347
 lidocaine hydrochloride; pharmacokinetics monitoring, pharmacists' role, 527
 magnesium; myocardial infarction therapy, mechanism of action, review, 588
 mexiletine; pharmacokinetics, middle-aged and elderly patients, 768
 nifedipine; toxicity, bezoars, sustained-action tablets, 849
 procainamide; blood levels, fluorescence polarization methods, 49
 procainamide hydrochloride; side effects, lack, pregnancy, 58
 quinidine; binding, blood levels, effects, ultrafiltration, temperature, 917; blood levels, fluorescence polarization vs. EMIT, 49
 sotalol hydrochloride; arrhythmia therapy, review, 883; FDA approvals, 176
Carnitine; dietary supplements; athletes, ergogenic effects, 900
Cathartics and laxatives
 glycerin; enemas vs. suppositories, neonates, 846
 labeling; nonprescription drugs, FDA regulations, 800
Catheters; intravenous; pressure, extravasation prediction, infants, 216
Cefepime; pharmacokinetics; cholecystectomy, acute cholecystitis, 134
Cefixime; toxicity; diarrhea, metronidazole therapy, 881
Cefotaxime; product withdrawal; nebacumab, 254
Central nervous system stimulants; tacrine hydrochloride; marketing, FDA approvals, 873
Cephalosporins
 cefepime; pharmacokinetics, cholecystectomy, acute cholecystitis, 134
 cefixime; toxicity, diarrhea, metronidazole therapy, 881
Cerebrovascular disorders
 therapy; review, 359
 ticlopidine; therapy, DUE criteria, 64
Certification; specialties; pharmacists, pharmaceutical care, ASHP, 923
Chickenpox; acyclovir; rational therapy, AAP recommendations, 175
Chloral hydrate; pediatrics; AAP recommendations, 876
Cholecystitis; cefepime; pharmacokinetics, cholecystectomy, 134
Cholestasis; ticlopidine hydrochloride; toxicity, 398
Ciprofloxacin; use; evaluation, criteria, 226
Cisapride; marketing; FDA approvals, 876
Cladribine
 leukemia; therapy, review, 805
 marketing; FDA approvals, 391
Clearance, see Excretion
Clindamycin; and aztreonam; colorectal surgery, prophylaxis, ASHP protocols, 399
Clinical Pharmacy
 acknowledgment to reviewers—October 1, 1992, to September 30, 1993, 923
 journals; merging *AJHP*, 526, 923
 instructions for submitting computer disks with revised manuscripts, 63, 535
 procedure for submission of manuscripts to journals published by the American Society of Hospital Pharmacists, 61, 533
Clinical studies
 nebacumab; marketing, withdrawal, toxicity, 254
 didanosine, comparison, zalcitabine; AIDS therapy, efficacy, 391
 drugs; alerts, NIH guidelines, news media, 637
 flosequinan; high dose, toxicity, mortality, 474
 replacement solutions; resuscitation, review, 415; resuscitation, selection, review, 335
 women; gender-related differences, FDA regulations, 395; new drugs, FDA regulations, 712
 zalcitabine, comparison, didanosine; AIDS therapy, efficacy, 391
Clomipramine; premenstrual syndrome; therapy, psychological symptoms, 181
Clonazepam; concomitant therapy, 222
Clonidine hydrochloride; lactation; maternal consumption,

- tion, infant blood levels, 178
Cobamide; dietary supplements; athletes, ergogenic effects, 900
Cognition
 enalapril maleate, comparison, hydrochlorothiazide, propranolol hydrochloride; toxicity, hypertension therapy, 300
 hydrochlorothiazide, comparison, enalapril maleate, propranolol hydrochloride; toxicity, hypertension therapy, 300
 propranolol hydrochloride, comparison, enalapril maleate, hydrochlorothiazide; toxicity, hypertension therapy, 300
Colitis
 cefixime; toxicity, metronidazole therapy, 881
 mesalamine; ulcerative, therapy, FDA approvals, 555
Colloids; replacement solutions; clinical studies, review, 415; selection, clinical studies, review, 335
Combined therapy
 cyclosporine and methotrexate; graft vs. host disease, marrow transplantation, 736
 methotrexate and cyclosporine; graft vs. host disease, marrow transplantation, 736
 ulcers; peptic, *H. pylori*, review, 34
Commentaries, 53, 527
Communication; clinical studies; results, prepublication clinical alerts, NIH, 637
Compounding; quinacrine hydrochloride; pleurodesis solutions, tablets, 693
Computers; programs; calculations, vancomycin dosage, 126
Contraceptives, injectable; medroxyprogesterone acetate; marketing, FDA approvals, 92
Contraceptives, oral; premenstrual syndrome; therapy, 181
Contraindications; itraconazole, 6
Correction Notices, 14, 558, 803, 881
 Are antiarrhythmic drugs obsolete? (Aug 1992 Commentary), 14
 Cladribine approved as first-line therapy for hairy cell leukemia (Jun 1993, News), 558
 Flumazenil: a benzodiazepine antagonist (Sep 1993, Drug Review), 803
 Zolpidem: a nonbenzodiazepine hypnotic for treatment of insomnia (Nov 1993, Drug Reviews), 881
Costs
 anticoagulants; thrombophlebitis therapy, 892
 cladribine; leukemia therapy, review, 805
 new-drug applications; Prescription Drug User Fee Act of 1992, pharmaceutical industry, 3
 replacement solutions; resuscitation, review, 335
CP Continuing Education, 67, 154, 235, 314, 383, 460, 542, 622, 699, 783, 860, 929
Creatinine; clearance; estimation, gynecologic neoplasms, 685
Crystalloids; replacement solutions; clinical studies, review, 415; selection, clinical studies, review, 335
Current Literature, 74, 161, 238, 318, 385, 465, 544, 624, 702, 785, 863, 932
Cyclosporine
 alone and with methotrexate; graft vs. host disease, prophylaxis, marrow transplantation, 736
 nephrotic syndrome; therapy, review, 429
 use; evaluation, criteria, transplant recipients, 696
Cystic fibrosis
 quinacrine hydrochloride; pneumothorax therapy, pleurodesis solution, 693
 therapy; review, 657
Cytotoxic agents, see **Antineoplastic agents**
- D**
- Dalteparin**; thrombophlebitis; low molecular weight heparins vs. unfractionated, 892
Danazol; premenstrual syndrome; therapy, 181
Dependence; opiates; levomethadyl therapy, regulations, 797
Depression; lithium; therapy, DUE criteria, 617
Devices; medical; clinical studies, women, FDA regulations, 712; reports, MEDWatch, FDA programs, 529
Dextran; replacement solutions; selection, clinical studies, review, 335
Dialysis
 hemo-; therapy, temafloxacin adverse reactions, 380
 peritoneal; peritonitis, effects, α -acid glycoprotein concentrations, 602
Diarrhea; cefixime; toxicity, metronidazole therapy, 881
Diazepam; seizures; therapy, ondansetron adverse reactions, 613
Didanosine
 comparison, zalcitabine; AIDS therapy, efficacy, NIAID clinical studies, 391
 toxicity; pancreatitis, review, 440
Dietary supplements; athletes; ergogenic effects, 900
Digoxin; atrial fibrillation; therapy, and atrial flutter, 721
Dimethyl sulfoxide; mechanism of action; anthracycline extravasation therapy, 560
Diphtheria and tetanus toxoids and pertussis vaccines; combination, *Haemophilus b* oligosaccharide conjugate vaccines; marketing, FDA approvals, 391
Diuretics
 furosemide; toxicity, pancreatitis, review, 440
 hypertension; therapy, protocols, 53
 nephrotic syndrome; complications, therapy, review, 429
 premenstrual syndrome; fluid retention therapy, 181
 thiazides; systolic hypertension therapy, geriatrics, review, 347
Documentation; drugs, adverse reactions; MEDWatch, FDA programs, 529
Dosage
 aldesleukin; DUE criteria, 853
 amlodipine besylate, 93
 anti-inflammatory agents; nonsteroidal, DUE criteria, 780
 atovaquone, 175; *P. carinii* pneumonia, therapy, review, 563
 cefepime; pharmacokinetics, cholecystectomy, acute cholecystitis, 134
 ciprofloxacin; DUE criteria, 226
 cisapride, 876
 cladribine, 391; leukemia therapy, review, 805
 cyclosporine; DUE criteria, transplant recipients, 696
 diphtheria and tetanus toxoids and pertussis vaccines, combination, *Haemophilus b* oligosaccharide conjugate vaccines; FDA approvals, marketing, 391
 enoxaparin, 471
 epoetin alfa; DUE criteria, 925
 felbamate, 713
 felodipine; hypertension therapy, review, 261
 fentanyl; transdermal pain therapy, 718
 flasteride; prostatic hypertrophy therapy, review, 15
 flomexin; high, toxicity, clinical studies, 474; high, toxicity, product withdrawal, 713
 flumazenil; DUE criteria, 536
 gentamicin sulfate; term newborn twins, 615
 heparin; estimation, pharmacokinetic models, 597
 indomethacin; injections, DUE criteria, neonates, 232
 isradipine; hypertension therapy, review, 261
 itraconazole, 6
 lidocaine hydrochloride; protocols, pharmacokinetics monitoring, pharmacists' role, 527
 lithium; DUE criteria, 617
 lomefloxacin; DUE criteria, 452
 loratadine, 474
 medroxyprogesterone acetate, 92
 meperidine hydrochloride; patient-controlled analgesia, DUE criteria, 150
 mesalamine, 555
 molgramostim; side effects, bone marrow transplantation, 520
 morphine sulfate; patient-controlled analgesia, DUE criteria, 150
 ofloxacin; DUE criteria, 452
 overdose; benzodiazepines, flumazenil therapy, overview, 691; benzodiazepines, flumazenil therapy, review, 641; benzodiazepines, flumazenil-use criteria, 536
 paclitaxel; refractory ovarian neoplasms therapy, review, 401
 phenytoin; unbound, blood levels prediction, equations, 913
 sotalol hydrochloride, 176; arrhythmia therapy, review, 883
 strontium chloride Sr 89, 632
 tacrine hydrochloride, 873
 teniposide, 6
 ticlopidine; DUE criteria, 64
 vancomycin hydrochloride; calculations, computers, 126; pharmacokinetics, hematologic malignancy, 515
 warfarin; DUE criteria, 307
 zolpidem tartrate; insomnia therapy, review, 814
Dosage forms
 glycerin; enemas vs. suppositories, neonates, 846
 leucovorin calcium, comparison, levoleucovorin calcium; i.v. vs. oral, equivalency, availability, 293
 levoleucovorin calcium, comparison, leucovorin calcium; i.v. vs. oral, equivalency, availability, 293
 mesalamine; sustained-action, oral, FDA approvals, 555
Dosage schedules
 anti-inflammatory agents; nonsteroidal, long-term therapy, DUE criteria, 780
 gallium nitrate; hypercalcemia therapy, malignancy-induced, review, 117
 metoclopramide; lactation stimulation, therapy, 479
 pamidronate disodium; hypercalcemia therapy, malignancy-induced, review, 117
 prednisone; allergic bronchopulmonary aspergillosis therapy, review, 24
Drug abuse; therapy; levomethadyl maintenance, narcotic treatment programs, 797
Drug administration routes
 leucovorin calcium, comparison, levoleucovorin calcium; i.v. vs. oral, equivalency, availability, 293
 levoleucovorin calcium, comparison, leucovorin calcium; i.v. vs. oral, equivalency, availability, 293
 quinacrine hydrochloride; intrapleural, pleurodesis solution, pneumothorax therapy, 693
Drug administration sites; intravenous; pressure, catheter extravasation prediction, infants, 216
Drug administration; cladribine; leukemia therapy, review, 805
Drug information; new drugs; evaluative reviews, publications, need, 306
Drug interactions
 drugs, nonprescription; new labeling requirements, FDA, 800
 itraconazole, 6
 sertraline hydrochloride and tranylcypromine sulfate; serotonergic syndrome, 222
 tranylcypromine sulfate and sertraline hydrochloride; serotonergic syndrome, 222
Drug Reaction Alerts, 74, 161, 238, 318, 385, 465, 544, 624, 702, 785, 863, 932
Drugs
 new; marketing, FDA approval, 1992, 247; publications, evaluative reviews, need, 306
 unapproved; imports, AIDS buyers' clubs, FDA regulations, 632
Drugs, adverse reactions
 see also **Toxicity**
 ondansetron hydrochloride; seizures, nausea therapy, 613
 photosensitivity; allergies, review, 580
 replacement solutions; review, 335
 reports; MEDWatch, FDA programs, 529
 temafloxacin hydrochloride; hemolytic anemia, kidney failure, 380
Drugs, availability
 leucovorin calcium, comparison, levoleucovorin calcium; equivalency, oral vs. i.v., 293
 levoleucovorin calcium, comparison, leucovorin calcium; equivalency, oral vs. i.v., 293
Drugs, body distribution
 aminoglycosides; pharmacokinetics, septic shock, 131
 clonidine hydrochloride; lactation, infant, blood levels, 178
 gentamicin sulfate; term newborn twins, 615
 midazolam hydrochloride; follicular fluid levels, in vitro fertilization, 770
 vancomycin; pharmacokinetics, geriatrics, 481; prediction, pharmacokinetics, 909
 vancomycin hydrochloride; pharmacokinetics, hematologic malignancy, 515
Drugs, investigational
 investigational new drugs; stavudine, AIDS therapy, parallel track policy, 7
 new-drug applications; accelerated, FDA approvals, final regulations, 253; clinical studies, women, FDA regulations, 712; Prescription Drug User Fee Act of 1992, FDA approvals, 3
Drugs, nonprescription; labeling; FDA regulations, 800
Drug use; evaluation; aldesleukin, criteria, 853; ciprofloxacin, criteria, 226; cyclosporine, criteria, transplant recipients, 696; epoetin alfa, criteria, 925; flumazenil, criteria, 536; indomethacin injections, criteria, neonates, 232; lithium, criteria, 617; lomefloxacin, ofloxacin, criteria, 452; NSAIDs criteria, 780; patient-controlled analgesia, criteria, 150; ticlopidine, criteria, 64; warfarin, criteria, 307
Ductus arteriosus; indomethacin; patent, therapy, DUE criteria, neonates, 232
DUE Criteria, 64, 150, 226, 307, 452, 536, 617, 696, 780, 853, 925
 aldesleukin, 853
 ciprofloxacin, 226
 cyclosporine, 696
 epoetin alfa, 925
 flumazenil, 536
 indomethacin, 232
 lithium, 617
 ofloxacin and lomefloxacin, 452
 nonsteroidal anti-inflammatory drugs (NSAIDs), 780
 patient-controlled analgesia, 150
 ticlopidine, 64
 warfarin, 307

E

- Editorials**, 306, 526, 691, 923
Context of a transition, 923
Judicious use of flumazenil, 691
The new *AJHP*, 526
Reviews of new drugs, 306
- Education, pharmaceutical; residencies; pharmaceutical care**, ASHP, 923
- Enalapril maleate**; comparison, hydrochlorothiazide, propranolol hydrochloride; effects, cognition, motor activity, quality of life, 300
- Encephalopathy**; muromonab-CD3; toxicity, graft rejection therapy, 610
- Endotoxins**; shock; septic, therapy, review, 829
- Enemas**; glycerin; vs. suppositories, neonates, 846
- Enoxaparin**
marketing; FDA approvals, 471
thrombophlebitis; low-molecular-weight heparins vs. unfractionated, 892
- Enzymes**; cystic fibrosis; digestive, therapy, 657
- Epilepsy**; felbamate; therapy, FDA approvals, 713
- Epoetin alfa**; use; evaluation, criteria, 925
- Equations**
aminoglycosides; pharmacokinetics, prediction, 909
creatinine; clearance, estimation, gynecologic neoplasms, 685
heparin; dosage estimation, 597
phenytoin; unbound, blood levels prediction, methodology, 913
- Equivalency, generic**
leucovorin calcium, comparison, levoleucovorin calcium; i.v. vs. oral, availability, 293
levoleucovorin calcium, comparison, leucovorin calcium; i.v. vs. oral, availability, 293
- Equivalency, therapeutic**
fentanyl, comparison, morphine; dosage, pain, 718
morphine, comparison, fentanyl; dosage, pain, 718
- Estrogen**; premenstrual syndrome; therapy, 181
- Estrogens**
estrogen; premenstrual syndrome therapy, 181
toxicity; pancreatitis, review, 440
- Excretion**
N-acetyl-L-tyrosine; excretion, infants, parenteral nutrition, 606
cefepime; clearance, cholecystectomy, acute cholecystitis, 134
creatinine; clearance, estimation, gynecologic neoplasms, 685
gentamicin sulfate; term newborn twins, 615
mexiletine; clearance, middle-aged and elderly patients, 768
vancomycin; clearance, prediction, 909; models, clearance, dosage calculations, 126
vancomycin hydrochloride; clearance, hematologic malignancy, 515
- Extravasation**
anthracyclines; toxicity, dimethyl sulfoxide therapy, 560
injections; i.v. pressure, prediction, infants, 216
- F**
- Fat emulsions**; intravenous; respiratory tract diseases, review, 276
- FDA Medical Products Reporting Form and Instructions**, 71, 531
- Felbamate**; marketing; FDA approvals, 713
- Felodipine**; hypertension; therapy, review, 261
- Fentanyl citrate**; concomitant therapy, 770
- Fentanyl**; dosage; transdermal pain therapy, 718
- Fertilization in vitro**; midazolam hydrochloride; follicular fluid levels, 770
- Filtration**; ultra; effects, quinidine blood levels, 917
- Flunarizine**; prostatic hypertrophy; therapy, review, 15
- Floresquinan**
product withdrawal; toxicity, 713
toxicity; high dosage, clinical studies, 474
- Flumazenil**
rational therapy; benzodiazepine overdose, overview, 691
therapy; benzodiazepine overdose, review, 641; respiratory depression, benzodiazepine toxicity, 483
use; evaluation, criteria, 536
- Fluoxetine**; premenstrual syndrome; therapy, psychological symptoms, 181
- Food and Drug Administration (U.S.)**
approvals; accelerated, final regulations, 253; amiodipine marketing, 93; atovaquone marketing, 175; cisapride marketing, 876; cladribine marketing, 391; enoxaparin marketing, 471; felbamate marketing, 713; itraconazole marketing, 6; loratadine marketing, 474; medroxyprogesterone marketing, 92; mesalamine marketing, 555; new drugs, evaluative reviews, need, 306; new drugs, 1992, 247; sotalol marketing, 176; strontium chloride Sr 89 marketing, 632; tacrine marketing, 873; teniposide marketing, 6; Tetramune marketing, 391
labeling; new regulations, nonprescription drugs, 800; proposed ruling, prescription, pediatrics, 6
MEDWatch; medical product reporting program, 529
Prescription Drug User Fee Act of 1992; laws, pharmaceutical industry, 3
regulations; clinical studies, women, 395; levomethadyl maintenance, narcotic treatment programs, 797; women, clinical studies, new drugs, 712
stavudine; AIDS therapy, parallel track policy approvals, 7
unapproved drugs; regulations, imports, AIDS buyers' clubs, 632
- Forms**; reports; MEDWatch, FDA programs, 529
- Formulations**; quinacrine hydrochloride; pleurodesis solutions, pneumothorax therapy, 693
- Furosemide**; toxicity; pancreatitis, review, 440
- G**
- Gallium nitrate**; hypercalcemia; therapy, malignancy-induced, review, 117
- Gastroesophageal reflux**; cisapride; therapy, FDA approvals, 876
- Gastrointestinal drugs**
bismuth; peptic ulcers, *H. pylori*, combined therapy, review, 34
cisapride; marketing, FDA approvals, 876
mesalamine; FDA approvals, 555
metoclopramide; lactation stimulation, therapy, 479
- Gene therapy**
cystic fibrosis; review, 657
research; genetic disorders, neoplasms, review, 488
- Genetic engineering**; gene therapy; research, review, 488
- Gentamicin**; pharmacokinetics; prediction, vancomycin pharmacokinetics, 909
- Gentamicin sulfate**
body distribution; pharmacokinetics, septic shock, 131
pharmacokinetics; term newborn twins, 615
- Geriatrics**
hypertension; systolic, therapy, review, 347; therapy, protocols, 53
mexiletine; pharmacokinetics, age, effects, 768
ticlopidine hydrochloride; toxicity, cholestasis, 398
vancomycin; pharmacokinetics, 481
- Ginseng**; dietary supplements; athletes, ergogenic effects, 900
- Glycerin**; dosage forms; enemas vs. suppositories, neonates, 846
- Globulin immune**
graft vs. host disease; prophylaxis, bone marrow transplantation, 736
therapy; altered immunocompetence, ACIP, 675
- Glomerulonephritis**; therapy; membranoproliferative, review, 429
- Glomerulosclerosis**; therapy; focal, review, 429
- Gonadorelin agonists**; premenstrual syndrome; therapy, 181
- Graft rejection**
cyclosporine; prophylaxis, DUE criteria, transplant recipients, 696
muromonab-CD3; therapy, encephalopathy toxicity, 610
- Graft vs. host disease**; therapy; prophylaxis, bone marrow transplantation, 736
- Grants**; Agency for Health Care Policy and Research; pharmacists' role, health care, 474
- Guidelines**; National Institutes of Health; clinical studies, news media, alerts, 637
- Guidelines, treatment, see Protocols**
- H**
- Haemophilus b oligosaccharide conjugate vaccines**; combination, diphtheria and tetanus toxoids and pertussis vaccines; marketing, FDA approvals, 391
- Haemophilus b polysaccharide conjugate vaccines**; immunogenicity; low, list, 176
- Half-life**
gentamicin sulfate; term newborn twins, 615
vancomycin; pharmacokinetics, geriatrics, 481
- vancomycin hydrochloride; pharmacokinetics, hematologic malignancy, 515
- Haloperidol lactate**; therapy; aggressive sex behavior, propofol toxicity, 449
- HA-1A see Nebacumab**
- Hay fever**; loratadine; therapy, FDA approvals, 474
- Health care**; pharmacists; role, grants, appropriate drug use, 474
- Health professions**
role; MEDWatch, FDA programs, 529
tuberculosis; surveillance programs, 167
- Heart failure**; flosequinan; congestive, high dose, toxicity, 474
- Helicobacter infections**; therapy; peptic ulcers, 34
- Helicobacter pylori**; therapy; peptic ulcers, review, 34
- Hematologic diseases**; vancomycin hydrochloride; neoplasms, pharmacokinetics, dosage, 515
- Heparin**
dosage; estimation, pharmacokinetic models, 597
low molecular weight; cerebrovascular disorders therapy, review, 359
myocardial infarction; therapy, 197
- Heparinoids**; cerebrovascular disorders; therapy, review, 359
- Heparins**; thrombophlebitis; low-molecular-weight vs. unfractionated, 892
- Histoplasmosis**; itraconazole; therapy, FDA approvals, 6
- HIV infections**; protocols; altered immunocompetence, therapy, ACIP, 675
- Hydrochlorothiazide**; comparison, enalapril maleate, propranolol hydrochloride; effects, cognition, motor activity, quality of life, 300
- Hyperalimentation, see Nutrition; parenteral**
- Hypercalcemia**
gallium nitrate; therapy, malignancy-induced, review, 117
pamidronate disodium; therapy, malignancy-induced, review, 117
- Hypertension**
amlodipine besylate; therapy, FDA approvals, 93
enalapril maleate, comparison, hydrochlorothiazide, propranolol hydrochloride; toxicity, quality of life, 300
felodipine; therapy, review, 261
hydrochlorothiazide, comparison, enalapril maleate, propranolol hydrochloride; toxicity, quality of life, 300
isradipine; therapy, review, 261
propranolol hydrochloride, comparison, enalapril maleate, hydrochlorothiazide; toxicity, quality of life, 300
protocols; therapy, 53
therapy; systolic, geriatrics, review, 347
- Hyperthyroidism**; amiodarone; toxicity, 774
- Hypoalbuminemia**; albumin human; therapy, effects, serum protein levels, 377
- Hyponatremia**; nutrition; parenteral, total, toxicity, 138
- Hypotensive agents**
clonidine hydrochloride; maternal consumption, lactation, infant blood levels, 178
enalapril maleate, comparison, hydrochlorothiazide, propranolol hydrochloride; effects, cognition and motor activity, quality of life, 300
felodipine; therapy, review, 261
hydrochlorothiazide, comparison, enalapril maleate, propranolol hydrochloride; effects, cognition and motor activity, quality of life, 300
hypertension; isolated systolic, geriatrics, review, 347
isradipine; therapy, review, 261
propranolol hydrochloride, comparison, enalapril maleate, hydrochlorothiazide; effects, cognition and motor activity, quality of life, 300
protocols; therapy, 53
- Hypothyroidism**; amiodarone; toxicity, 774
- I**
- Iatrogenic diseases, see Drugs, adverse reactions**
- Immunization**
diphtheria and tetanus toxoids and pertussis and *Haemophilus influenzae*; conjugate vaccines, pediatrics, FDA approvals, 391
Haemophilus influenzae; conjugate vaccines, low immunogenicity, list, 176
tuberculosis; BCG vaccines, health professions, surveillance programs, 167
vaccines; altered immunocompetence, ACIP protocols, 675
- Immunoassay**
enzyme multiplied; vs. fluorescence polarization, an-

- tiarrhythmic agents, 49
fluorescence polarization; vs. enzyme multiplied, anti-tiarrhythmic agents, 49
- Immunocompetence**; protocols; altered, globulin immune, immunization, ACIP, 675
- Immunogenicity**; *Haemophilus b* polysaccharide conjugate vaccines; low, list, 176
- Immunologic deficiency syndromes**; protocols; vaccines, globulin immune, ACIP, 675
- Immunosuppression**; vitamin A; immunomodulating effects, review, 506
- Immunosuppressive agents**
azathioprine; toxicity, pancreatitis, review, 440
cyclosporine; alone and with methotrexate, graft vs. host disease, marrow transplantation, 736; DUE criteria, transplant recipients, 696; nephrotic syndrome, review, 429
methotrexate; graft vs. host disease, marrow transplantation, 736
murinomab-CD3; toxicity, encephalopathy, graft rejection therapy, 610
tacrolimus; graft vs. host disease, marrow transplantation, 736
thalidomide; graft vs. host disease, marrow transplantation, 736
- Immunotherapy**
antithymocyte globulin; graft vs. host disease, marrow transplantation, 736
globulin immune; graft vs. host disease, marrow transplantation, 736
molgramostim; side effects, bone marrow transplantation, 520
nebacumab; clinical studies, marketing, withdrawal, toxicity, 254
protocols; altered immunocompetence, ACIP, 675
sargramostim; agranulocytosis therapy, sulfasalazine toxicity, 179; dosage, 520
vitamin A; immunomodulating effects, review, 506
zolomomab artoix; graft vs. host disease, marrow transplantation, 736
- Imports**; unapproved drugs; AIDS buyers' clubs, FDA regulations, 632
- Indomethacin**; use; evaluation, criteria, neonates, 232
- Industry, pharmaceutical**
advertising; accelerated drug approvals, FDA regulations, 253
labeling; nonprescription drugs, FDA regulations, 800; prescription drugs, pediatric, FDA ruling, 6
new-drug applications; clinical studies, women, FDA regulations, 712
Prescription Drug User Fee Act of 1992; laws, FDA approvals, 3
- Infections**; vitamin A; immunomodulating effects, review, 506
- Injections**
anthracyclines; extravasation, dimethyl sulfoxide therapy, 560
catheters; i.v. pressure, extravasation prediction, infants, 216
ciprofloxacin; intravenous therapy, infections, DUE criteria, 226
indomethacin; DUE criteria, neonates, 232
medroxyprogesterone acetate; marketing, FDA approvals, 92
- Insomnia**; zolpidem tartrate; therapy, review, 814
- Interleukin inhibitors**; shock; septic, therapy, review, 829
- Iodine I 131**; hyperthyroidism; therapy, amiodarone toxicity, 774
- Isoosorbide dinitrate**; hypertension; systolic, therapy, geriatrics, review, 347
- Isradipine**; hypertension; therapy, review, 261
- Itraconazole**; marketing; FDA approvals, 6

J

- Joint National Committee on the Detection, Evaluation and Treatment of High Blood Pressure**; reports; hypertension therapy, protocols, 53
- Journals**
American Journal of Hospital Pharmacy; merging, *Clinical Pharmacy*, 526, 923
Clinical Pharmacy; merging, *AJHP*, 526, 923

K

- Kidney failure**; temafloxacin hydrochloride; adverse reactions, hemolytic anemia, 380

L

- Labeling**
drugs, nonprescription; FDA regulations, 800
pediatrics; prescriptions, FDA proposed ruling, 6
- Lactation**
clonidine hydrochloride; maternal consumption, infant blood levels, 178
therapy; stimulation, 479
- Laws**; Prescription Drug User Fee Act of 1992; pharmaceutical industry, FDA approvals, 3
- Letters**, 13, 178, 255, 398, 481, 718, 802, 881
Clonidine and breast-feeding, 178
Comment on ASHP therapeutic guidelines, 399
Dosage of transdermal fentanyl, 718
Ketoconazole and gastric acidity, 802
Long-term dobutamine therapy, 13
Pharmacokinetics of oxaprozin, 255
Prophylaxis with aztreonam plus metronidazole during appendectomy, 803
Recognition of severe cefixime-induced diarrhea, 881
Relative safety and efficacy of pravastatin, 256
Sargramostim for sulfasalazine-induced agranulocytosis, 179
Ticlopidine-induced cholestatic jaundice, 398
Use and safety of sumatriptan, 258
Vancomycin pharmacokinetics in elderly patients, 481
- Leucovorin calcium**; comparison, levoleucovorin calcium; equivalency, oral vs. i.v., availability, 293
- Leukemia**
cladribine; hairy cell, therapy, FDA approvals, 391; therapy, review, 805
teniposide; lymphocytic, therapy, FDA approvals, 6
Levoleucovorin calcium; comparison, leucovorin calcium; equivalency, oral vs. i.v., availability, 293
- Levomethadyl acetate**; therapy; maintenance, narcotic treatment programs, 797
- Levothyroxine sodium**; hypothyroidism; therapy, amiodarone toxicity, 774
- Lidocaine hydrochloride**; pharmacokinetics; monitoring, pharmacists' role, 527
- Literature**; new drugs; evaluative reviews, need, 306
- Lithium**; use; evaluation, criteria, 617
- Lomefloxacin**; use; evaluation, criteria, 452
- Loratadine**; marketing; FDA approvals, 474

M

- Magnesium**; myocardial infarction; therapy, mechanism of action, review, 588
- Marketing**
amlodipine besylate; FDA approvals, 93
atovaquone; FDA approvals, 175
cisapride; FDA approvals, 876
cladribine; FDA approvals, 391
diphtheria and tetanus toxoids and pertussis vaccines, combination, *Haemophilus b* oligosaccharide conjugate vaccines; FDA approvals, 391
enoxaparin; FDA approvals, 471
felbamate; FDA approvals, 713
flosequinan; product withdrawal, 713
itraconazole; FDA approvals, 6
loratadine; FDA approvals, 474
medroxyprogesterone acetate; FDA approvals, 92
mesalamine; FDA approvals, 555
nebacumab; clinical studies, withdrawal, toxicity, 254
new drugs; evaluative reviews, need, 306; FDA approval, 1992, 247
sotalol hydrochloride; FDA approvals, 176
strontium chloride Sr 89; FDA approvals, 632
tacrine hydrochloride; FDA approvals, 873
teniposide; FDA approvals, 6
- Measles**; vitamin A; immunomodulating effects, review, 506
- MedWatch**; reports; FDA programs, 529
- Mechanism of action**
amiodarone; toxicity, thyroid dysfunction, 774
atovaquone; *P. carinii* pneumonia, therapy, review, 563
cladribine; leukemia therapy, review, 805
dimethyl sulfoxide; anthracycline extravasation therapy, 560
flumazenil; review, 641
magnesium; myocardial infarction therapy, review, 588
replacement solutions; resuscitation, review, 335
temafloxacin hydrochloride; adverse reactions, hemolytic anemia, 380
vitamin A; immunomodulating effects, review, 506

- Medroxyprogesterone acetate**; marketing; FDA approvals, 92
- Meperidine hydrochloride**; use; evaluation, criteria, patient-controlled analgesia, 150
- Mercaptopurine**; toxicity; pancreatitis, review, 440
- Mesalamine**; marketing; FDA approvals, 555
- Methodology**
clinical studies; women, FDA regulations, 712
creatinine; clearance, estimation, gynecologic neoplasms, 685
heparin; dosage estimation, pharmacokinetic models, 597
injections; i.v. pressure, extravasation prediction, infants, 216
phenytoin; unbound, blood levels prediction, equations, 913
quinidine; blood levels, effects, ultrafiltration, temperature, 917
vancomycin; pharmacokinetics, prediction, 909
vancomycin hydrochloride; dosage, calculations, computers, 126
- Methotrexate**
alone and with cyclosporine; graft vs. host disease, prophylaxis, marrow transplantation, 736
asthma; therapy, overview, 762
- N-5-Methyltetrahydrofolate**; blood levels; leucovorin-levoleucovorin generic equivalency, 293
- Metoclopramide**; lactation; stimulation, 479
- Metronidazole**
and aztreonam; colorectal surgery, prophylaxis, ASHP protocols, 399
diarrhea; therapy, cefixime toxicity, 881
ulcers; peptic, combined therapy, *H. pylori*, review, 34
- Mexiletine**; pharmacokinetics; effects, age, geriatrics, 768
- Midazolam hydrochloride**; body distribution; follicular fluid levels, in vitro fertilization, 770
- Minerals**; and vitamins; dietary supplements, athletes, ergogenic effects, 900
- Models**
heparin; pharmacokinetics, dosage estimation, 597
vancomycin; clearance, dosage calculations, 126
- Molgramostim**; toxicity; side effects, bone marrow transplantation, 520
- Morphine sulfate**; use; evaluation, criteria, patient-controlled analgesia, 150
- Morphine**; equivalency, therapeutic; fentanyl, transdermal dosage, 718
- Mortality**
anticoagulants; myocardial infarction therapy, 197
flosequinan; high dose, toxicity, clinical studies, 474; toxicity, product withdrawal, 713
- Motor activity**
enalapril maleate, comparison, hydrochlorothiazide, propranolol hydrochloride; toxicity, hypertension therapy, 300
hydrochlorothiazide, comparison, enalapril maleate, propranolol hydrochloride; toxicity, hypertension therapy, 300
propranolol hydrochloride, comparison, enalapril maleate, hydrochlorothiazide; toxicity, hypertension therapy, 300
- Mucolytic agents**; cystic fibrosis; therapy, review, 657
- Murinomab-CD3**; toxicity; encephalopathy, graft rejection therapy, 610
- Mycobacterium tuberculosis**; resistance; antituberculars, health professions, surveillance programs, 167
- Myocardial infarction**
magnesium; therapy, mechanism of action, review, 588
therapy, 197

N

- Nadroparin**; thrombophlebitis; low-molecular-weight heparins vs. unfractionated, 892
- National Institute of Allergy and Infectious Diseases**
didanosine, comparison, zalcitabine; AIDS therapy, efficacy, clinical studies, 391
zalcitabine, comparison, didanosine; AIDS therapy, efficacy, clinical studies, 391
- National Institutes of Health**; guidelines; clinical studies, news media, alerts, 637
- National Institute on Drug Abuse**; regulations; levomethadyl maintenance, narcotic treatment programs, 797
- Nausea**; ondansetron hydrochloride; therapy, adverse reactions, seizures, 613
- Nebacumab**; clinical studies; and marketing withdrawal, toxicity, 254
- Neoplasms**
aldesleukin; therapy, DUE criteria, 853

creatinine; clearance, estimation, gynecologic neoplasms, 685
 epoetin alfa; anemia therapy, DUE criteria, 925
 gallium nitrate; hypercalcemia therapy, malignancy-induced, review, 117
 gene therapy; research, review, 488
 pamidronate disodium; hypercalcemia therapy, malignancy-induced, review, 117
 vancomycin hydrochloride; hematologic, pharmacokinetics, dosage, 515
Nephrosis; therapy; lipid, therapy, review, 429
Nephrotic syndrome; therapy; review, 429
News, 3, 91, 167, 247, 327, 391, 471, 551, 632, 712, 793, 873
 Acyclovir should not be used routinely for chickenpox, says pediatrics academy, 175
 AHA issues report on Kawasaki disease, 555
 AHCPR awards 14 grants for patient outcomes research, 474
 American Heart Association updates life support guidelines, 171
 Amlodipine approved for hypertension, angina therapy, 93
 Atovaquone to be marketed as oral therapy for *Pneumocystis carinii* pneumonia, 175
 Book correction notice, 637
 CDC issues recommendations for rehydration and nutritional therapy for children with acute diarrhea, 92
 CDC revises AIDS case definition, 254
 Centocor suspends HA-1A testing, halts foreign sales, 254
 Cisapride marketed for use in gastroesophageal reflux disease, 876
 Cladribine approved as first-line therapy for hairy cell leukemia, 391
 Combination vaccine approved for use in children, 391
 Conference, reports address public-health implications of tuberculosis, 167
 Consensus recommendations for antithrombotic therapy updated, 92
 Continued use of chloral hydrate justified, concludes pediatrics academy, 876
 Easier-to-use pirbuterol inhaler marketed, 715
 FDA clears 26 new drugs for marketing in 1992, 247
 FDA issues regulations on accelerated drug-approval process, 253
 FDA plans policy change on inclusion of women in clinical trials, 395
 FDA proposes more stringent pediatric-use labeling of prescription drug products, 6
 FDA reiterates personal-use importation policy to buyers' clubs, 632
 FDA user fees approved, 3
 Flosequin withdrawn from market, 713
 Four-drug regimen, directly observed therapy urged for initial tuberculosis therapy, 793
 Guidelines for release of clinical alerts set, 637
 Higher folic acid intake could prevent many common birth defects, says pediatrics academy, 879
 Intensive care units see increase in resistant enterococci, 797
 Itraconazole released for blastomycosis and histoplasmosis therapy, 6
 I.V. antimicrobials not indicated for presumed Lyme disease, say rheumatology, infectious diseases groups, 876
 Levomethadyl acetate to be used in narcotic treatment programs, 797
 Low-molecular-weight heparin to be marketed, 471
 Medroxyprogesterone acetate granted contraceptive indication in U.S., 92
 New antiepilepsy drug, felbamate, marketed, 713
 New FDA policy encourages inclusion of women in clinical trials, 712
 News Briefs, 7, 93, 176, 254, 331, 395, 474, 555, 637, 715, 879
 Nonionic contrast medium for MRI procedures marketed, 93
 Non-sedating antihistamine approved by FDA, 474
 Nutrition support guidelines published, 715
 Oral mesalamine formulation to be marketed, 555
 Patient deaths halt flutamide trials, 715
 Pediatrics academy releases guidelines for prevention of neonatal group B streptococcal infection, 91
 Physician group releases guidelines on preventive hormonal therapy, 327
 Preliminary data show mortality risk from high-dose flosequin, 474
 Preliminary study analysis suggests similar efficacy for didanosine and zalcitabine, 391
 Preliminary study findings fuel debate over timing of zidovudine therapy, 551
 Public Health Service issues recommendations for

prophylaxis against *Mycobacterium avium* complex, 797
Radiopharmaceutical approved for relief of pain caused by bone metastases, 632
 Sixteen PedvaxHIB vaccine lots have low immunogenicity, 176
 Sotalol marketed for life-threatening arrhythmias, 176
 Stavudine made available under parallel track policy, 7
 Study provides additional support for warfarin use by patients with atrial fibrillation, 93
 Study shows deleterious effects from digoxin withdrawal, 713
 Study shows diazepam use during febrile illnesses reduces risk of recurrent febrile seizures, 800
 Surveillance study adds to database on seroconversion rates and zidovudine use after occupational exposures, 636
 Tacrine granted marketing approval for Alzheimer's disease, 873
 Teniposide granted marketing approval, 6
 Three categories of nonprescription drug products to carry new warnings, 800
 Upcoming Specialty Meetings, 7, 93, 254, 331, 395, 475, 558, 637, 800, 879
News media; clinical studies; clinical alerts, NIH guidelines, 849
Nifedipine; toxicity; bezoars, sustained-action tablets, 849
Nomograms
 phenytoin; dosage, unbound, blood levels prediction, 913
 vancomycin hydrochloride; initial dosage schedules, hematologic malignancy, 515
Nutrition
 diet; and supplements, athletes, review, 900
 parenteral; N-acetyl-L-tyrosine, excretion, infants, 606;
 albumin effects, serum protein levels, hypoalbuminemia, 377; total, toxicity, sodium disorders, 138
 support; respiratory tract diseases, review, 276
O
Octacosanol; dietary supplements; athletes, ergogenic effects, 900
Ofloxacin; use; evaluation, criteria, 452
Ondansetron hydrochloride; adverse reactions; seizures, nausea therapy, 613
Opiates; levomethadyl acetate; maintenance therapy, narcotic treatment programs, 797
Organizations; American Society of Hospital Pharmacists; AJHP, *Clinical Pharmacy*, merging, 526, 923
Ovarian neoplasms; paclitaxel; refractory, therapy, review, 401
Oxygen radical scavengers; dimethyl sulfoxide; anthracycline extravasation therapy, 560

P

Paclitaxel; ovarian neoplasms; refractory, therapy, review, 401
Pain
 anti-inflammatory agents; nonsteroidal, long-term therapy, DUE criteria, 780
 fentanyl; transdermal therapy, dosage, 718
 patient-controlled analgesia; therapy, DUE criteria, 150
 strontium chloride Sr 89; therapy, bone neoplasms, FDA approvals, 632
Pamidronate disodium; hypercalcemia; therapy, malignancy-induced, review, 117
Pancreatitis
 asparaginase; toxicity, review, 440
 azathioprine; toxicity, review, 440
 didanosine; toxicity, review, 440
 estrogens; toxicity, review, 440
 furosemide; toxicity, review, 440
 mercaptopurine; toxicity, review, 440
 pentamidine; toxicity, review, 440
 sulfonamides; toxicity, review, 440
 sulindac; toxicity, review, 440
 tetracyclines; toxicity, review, 440
 thiazides; toxicity, review, 440
 valproic acid; toxicity, review, 440
Parenterals, see **Injections**
Patches transdermal; fentanyl; dosage, pain therapy, 718
Patient-controlled analgesia; protocols; DUE criteria, 150

Patients

drugs, personal; unapproved, imports, AIDS buyers' clubs, FDA regulations, 632
 inpatients; lithium, DUE criteria, 617; lomefloxacin, ofloxacin, DUE criteria, 452; NSAIDs, DUE criteria, 780; ticlopidine, DUE criteria, 64; warfarin, DUE criteria, 307
 outpatients; flumazenil, DUE criteria, 536; lithium, DUE criteria, 617; lomefloxacin, ofloxacin, DUE criteria, 452; NSAIDs, DUE criteria, 780; ticlopidine, DUE criteria, 64; warfarin, DUE criteria, 307
Pediatrics
 N-acetyl-L-tyrosine; excretion, infants, parenteral nutrition, 606
 acyclovir; chickenpox therapy, AAP recommendations, 175
 bronchiolitis; therapy, review, 95
 chloral hydrate; AAP recommendations, 876
 clonidine hydrochloride; maternal consumption, lactation, infant blood levels, 178
 diphtheria and tetanus toxoids and pertussis vaccines, combination, *Haemophilus b* oligosaccharide conjugate vaccines; immunization, FDA approvals, 391
Haemophilus b polysaccharide conjugate vaccines; low immunogenicity, list, 176
 injections; I.V. pressure, catheter extravasation prediction, infants, 216
 neonates; gentamicin pharmacokinetics, term newborn twins, 615; glycerin enemas vs. suppositories, 846; indomethacin injections, DUE criteria, 232
 prescriptions; labeling, FDA proposed ruling, 6
 teniposide; lymphocytic leukemia therapy, FDA approvals, 6
Penicillins; amoxicillin; peptic ulcers, *H. pylori*, combined therapy, review, 34
Pentamidine; toxicity; pancreatitis, review, 440
Peritonitis; dialysis; peritoneal, effects, α -acid glycoprotein concentrations, 602
Pharmacists; role; health care, grants, 474; lidocaine, pharmacokinetics monitoring, 527
Pharmaceutical care; American Society of Hospital Pharmacists; journals, merging, 923
Pharmaceutical services; research; grants, appropriate drug use, 474
Pharmacodynamics; atovaquone; *P. carinii* pneumonia, therapy, review, 563
Pharmacokinetics
 N-acetyl-L-tyrosine; excretion, infants, parenteral nutrition, 606
 aminoglycosides; body distribution, septic shock, 131; prediction, vancomycin pharmacokinetics, 909
 amlodipine besylate, 93
 atovaquone, 175; *P. carinii* pneumonia, therapy, review, 563
 cefepime; cholecystectomy, acute cholecystitis, 134
 cisapride, 876
 cladribine, 391; leukemia therapy, review, 805
 enoxaparin, 471
 felbamate, 713
 felodipine; hypertension therapy, review, 261
 finasteride; prostatic hypertrophy therapy, review, 15
 flumazenil; review, 641
 gentamicin sulfate; term newborn twins, 615
 heparin; models, dosage estimation, 597
 isradipine; hypertension therapy, review, 261
 itraconazole, 6
 lidocaine hydrochloride; monitoring, pharmacists' role, 527
 loratadine, 474
 medroxyprogesterone acetate, 92
 mesalamine, 555
 mexiletine; effects, age, geriatrics, 768
 paclitaxel; refractory ovarian neoplasms therapy, review, 401
 sotalol hydrochloride, 176; arrhythmia therapy, review, 883
 strontium chloride Sr 89, 632
 tacrine hydrochloride, 873
 teniposide, 6
 vancomycin; geriatrics, 481; prediction, aminoglycoside pharmacokinetics, 909
 vancomycin hydrochloride; dosage, hematologic malignancy, 515
 zolpidem tartrate; insomnia therapy, review, 814
Pharmacy and therapeutics committee; new drugs; decisions, evaluative reviews, need, 306
Pharmacy, institutional, hospital; quality assurance; programs, aldesleukin DUE criteria, 853; programs, ciprofloxacin, DUE criteria, 226; programs, cyclosporine DUE criteria, 696; programs, epoetin alfa DUE criteria, 925; programs, flumazenil DUE criteria, 536; programs, indomethacin injections, DUE criteria, neones, 232; programs, lithium DUE criteria, 617; pro-

grams, lomefloxacin, ofloxacin, DUE criteria, 452; programs, NSAIDs, DUE criteria, 780; programs, patient-controlled analgesia, DUE criteria, 150; programs, ticlopidine DUE criteria, 64; programs, warfarin DUE criteria, 307

Pharmacy, institutional; new drugs; evaluative reviews, need, 306

Phenytoin; blood levels; prediction, equations, unbound concentration, 913

Photosensitivity; drugs; toxicity, review, 580

Placental transfer; procainamide hydrochloride; lack, neonates, 58

Platelet aggregation inhibitors
glomerulonephritis; membranoproliferative, therapy, review, 429
ticlopidine; DUE criteria, 64

Pneumonia; atovaquone; *P. carinii*, therapy, FDA approvals, 175; *P. carinii*, therapy, review, 563

Pneumothorax; quinacrine hydrochloride; therapy, pleurodesis solution, cystic fibrosis, 693

Polymyalgia rheumatica; therapy; review, 571

Postmarketing surveillance
drugs, adverse reactions; MEDWatch, FDA programs, 529
regulations; FDA accelerated drug approvals, 253

Prednisolone; polymyalgia rheumatica; therapy, review, 571

Prednisone
aspergillosis; allergic bronchopulmonary, therapy, review, 24
polymyalgia rheumatica; therapy, review, 571

Pregnancy; procainamide hydrochloride; side effects, lack, 58

Premenstrual syndrome; therapy; review, 181

Prescription Drug User Fee Act of 1992; laws; pharmaceutical industry, FDA approvals, 3

Prescriptions; drugs; appropriate use, grants, pharmacists' role, 474; pediatric labeling, FDA proposed ruling, 6

Pressure; catheters; extravasation prediction, infants, 216

Procainamide; blood levels; fluorescence polarization methods, 49

Procainamide hydrochloride; toxicity; side effects, lack, pregnancy, 58

Product withdrawal
flosequinan; toxicity, high dose, 713
nebucumab; foreign market, toxicity, 254

Professional fees; new-drug applications; Prescription Drug User Fee Act of 1992, pharmaceutical industry, 3

Progesterone; premenstrual syndrome; therapy, 181

Progestins; progesterone; premenstrual syndrome therapy, 181

Propofol; toxicity; aggressive sex behavior, 449

Propranolol hydrochloride; comparison, enalapril maleate, hydrochlorothiazide; effects, cognition, motor activity, quality of life, 300

Propylthiouracil; hyperthyroidism; therapy, amiodarone toxicity, 774

Prostaglandin inhibitors; premenstrual syndrome; therapy, 181

Prostatic hypertrophy; finasteride; therapy, review, 15

Prostatitis; ciprofloxacin; therapy, DUE criteria, 226

Protocols
acyclovir; chickenpox therapy, AAP recommendations, 175
aldesleukin; DUE criteria, 853
American Society of Hospital Pharmacists; antimicrobial prophylaxis, colorectal surgery, 399
anti-inflammatory agents; nonsteroidal, DUE criteria, 780
chloral hydrate; pediatrics, AAP recommendations, 876
ciprofloxacin; DUE criteria, 226
cyclosporine; DUE criteria, transplant recipients, 696
epoetin alfa; DUE criteria, 925
flumazenil; DUE criteria, 536
hypotensive agents; therapy, 53
immunization; vaccines, altered immunocompetence, ACIP, 675
immunotherapy; altered immunocompetence, ACIP, 675
indomethacin; injections, DUE criteria, neonates, 232
lidocaine hydrochloride; dosage, pharmacokinetics monitoring, pharmacists' role, 527
lithium; DUE criteria, 617
lomefloxacin; DUE criteria, 452
ofloxacin; DUE criteria, 452
patient-controlled analgesia; DUE criteria, 150
stavudine; AIDS therapy, parallel track policy, FDA approvals, 7
ticlopidine; DUE criteria, 64
warfarin; DUE criteria, 307

Publications

American Society of Hospital Pharmacists; *AJHP, Clinical Pharmacy*, merging, 526, 923
new drugs; evaluative reviews, need, 306

Purchasing; unapproved drugs; AIDS buyers' clubs, FDA regulations, 632

Q

Quality assurance; hospital pharmacy; programs, aldesleukin DUE criteria, 853; programs, ciprofloxacin, DUE criteria, 226; programs, cyclosporine DUE criteria, 696; programs, DUE criteria, 64; programs, epoetin alfa DUE criteria, 925; programs, flumazenil, DUE criteria, 536; programs, indomethacin injections, DUE criteria, neonates, 232; programs, lithium DUE criteria, 617; programs, lomefloxacin, ofloxacin, DUE criteria, 452; programs, NSAIDs, DUE criteria, 780; programs, patient-controlled analgesia, DUE criteria, 150; programs, warfarin DUE criteria, 307

Quality of life

enalapril maleate, comparison, hydrochlorothiazide, propranolol hydrochloride; cognition and motor activity, effects, hypertension therapy, 300
hydrochlorothiazide, comparison, enalapril maleate, propranolol hydrochloride; cognition and motor activity, effects, hypertension therapy, 300
propranolol hydrochloride, comparison, enalapril maleate, hydrochlorothiazide; cognition and motor activity, effects, hypertension therapy, 300

Quinacrine hydrochloride; pneumothorax; therapy, pleurodesis solution, cystic fibrosis, 693

Quinidine
binding; plasma, effects, ultrafiltration, 917
blood levels; fluorescence polarization vs. EMIT, 49

Quinolones
ciprofloxacin; DUE criteria, 226
lomefloxacin; DUE criteria, 452
ofloxacin; DUE criteria, 452
photosensitivity; toxicity, review, 580
temafloxacin hydrochloride; adverse reactions, hemolytic anemia, 380

R

Radiopharmaceuticals; strontium chloride Sr 89; FDA approvals, 632

Rational therapy
acyclovir; chickenpox, AAP recommendations, 175
fentanyl; transdermal pain therapy, morphine replacement, 718
flumazenil; benzodiazepine overdose, overview, 691
nutrition; parenteral, monitoring, serum protein levels, hypoalbuminemia, 377
research; pharmacy, grants, 474

Regulations
clinical studies; women, gender-related differences, 395
Food and Drug Administration; labeling, nonprescription drugs, 800; prescriptions, labeling, pediatrics, 6; unapproved drugs, imports, AIDS buyers' clubs, 632; women, clinical studies, new drugs, 712
levomethadyl acetate; maintenance, narcotic treatment programs, 797
new-drug applications; accelerated, FDA approvals, 253

Replacement solutions
albumin human; effects, serum protein levels, parenteral nutrition, 377
resuscitation; clinical studies, review, 415; selection, clinical studies, review, 335

Reports
drugs, adverse reactions; MEDWatch, FDA programs, 529
hypertension; therapy, protocols, 53

Research
gene therapy; genetic disorders, neoplasms, review, 488
pharmacy; grants, appropriate drug use, 474

Resistance; antituberculars; *M. tuberculosis*, health professions, surveillance programs, 167

Respiratory tract diseases; nutrition; therapy, review, 276

Resuscitation; replacement solutions; clinical studies, review, 415; selection, clinical studies, review, 335

Ribavirin; bronchiolitis; therapy, pediatrics, review, 95

Ringer's injection lactated; replacement solutions; selection, clinical studies, review, 335

S

Sargramostim
agranulocytosis; therapy, sulfasalazine toxicity, 179
comparison, molgramostim; dosage, 520

Sclerosing agents; quinacrine hydrochloride; pneumothorax therapy, pleurodesis solutions, cystic fibrosis, 693

Seizures; ondansetron hydrochloride; adverse reactions, nausea therapy, 613

Self-study Materials, 243, 548
Concepts in Immunology and Immunotherapeutics, Second Edition, 243
Pharmacotherapy Self-Assessment Program: Module 1, Cardiovascular, 244
Pharmacotherapy Self-Assessment Program: Module 2, Infectious Diseases, 548

Sertraline hydrochloride; interactions; tranylcypromine, serotonergic syndrome, 222

Sex behavior; propofol; aggressive, toxicity, 449

Sex
clinical studies; women, FDA regulations, 395
patients; effects, lack, heparin dosage estimation, 597

Shock
aminoglycosides; septic, body distribution, 131
therapy; septic, biotechnology, review, 829

Smoking; effects; heparin dosage estimation, 597

Sodium chloride
injections; replacement solutions, selection, clinical studies, review, 335
replacement solutions; clinical studies, review, 415

Solutions; quinacrine hydrochloride; pleurodesis, pneumothorax therapy, 693

Sotalol hydrochloride
arrhythmia; therapy, review, 883
marketing; FDA approvals, 176

Starches; replacement solutions; selection, clinical studies, review, 335

Stavudine; acquired immunodeficiency syndrome; therapy, parallel track policy, FDA approvals, 7

Steroids, corticosteroids
asthma; dependent, methotrexate therapy, overview, 762
cystic fibrosis; therapy, review, 657
graft vs. host disease; prophylaxis, bone marrow transplantation, 736
nephrotic syndrome; therapy, review, 429
prednisolone; polymyalgia rheumatica therapy, review, 571
prednisone; allergic bronchopulmonary aspergillosis therapy, review, 24; polymyalgia rheumatica therapy, review, 571

Storage; cladribine; leukemia therapy, review, 805

Strontium chloride Sr 89; marketing; FDA approvals, 632

Sulfasalazine; toxicity; agranulocytosis, sargramostim therapy, 179

Sulfonamides
sulfasalazine; toxicity, agranulocytosis, sargramostim therapy, 179
toxicity; pancreatitis, review, 440

Sulindac; toxicity; pancreatitis, review, 440

Suppositories; glycerin; vs. enemas, neonates, 846

Surgery
aminoglycosides; postoperative septic shock, body distribution, 131
anti-infective agents; colorectal, prophylaxis, ASHP protocols, 399
cefepime; pharmacokinetics, cholecystectomy, acute cholecystitis, 134
enoxaparin; thrombosis prophylaxis, FDA approvals, 471
epoetin alfa; anemia therapy, neoplasms, DUE criteria, 925
patient-controlled analgesia; postoperative pain, DUE criteria, 150

Sustained-action medications
mesalamine; oral marketing, FDA approvals, 555
nifedipine; toxicity, bezoars, 849

Sympatholytic agents; β blockers; atrial fibrillation, atrial flutter therapy, 721; hypertension therapy, protocols, 53; systolic hypertension therapy, geriatrics, review, 347

Sympathomimetic agents; β agonists; bronchiolitis, aerosols, therapy, pediatrics, review, 95; cystic fibrosis therapy, review, 657

T

Tables
nifedipine; sustained-action, bezoars, toxicity, 849

quinacrine hydrochloride; formulations, pleurodesis solutions, pneumothorax therapy, 693

Tacrine hydrochloride; marketing; FDA approvals, 873

Tacrolimus; graft vs. host disease; prophylaxis, bone marrow transplantation, 736

Tamoxifen; premenstrual syndrome; therapy, mastodynia, 181

Temafloxacin hydrochloride; adverse reactions; hemolytic anemia, kidney failure, 380

Temperature; quinidine; effects, blood levels, ultrafiltration, 917

Teratogenicity; procainamide hydrochloride; pregnancy, 58

Tetracycline; bismuth and metronidazole; peptic ulcer therapy, *H. pylori*, review, 34

Tetracyclines
photosensitivity; toxicity, review, 580
tetracycline; peptic ulcers, *H. pylori*, combined therapy, review, 34
toxicity; pancreatitis, review, 440

Tetrahydrolic acid; blood levels; leucovorin-levoleucovorin generic equivalency, 293

Tetramine; diphtheria and tetanus toxoids and pertussis vaccines; combination, *Haemophilus b* oligosaccharide conjugate vaccines, 391

Thalidomide; graft vs. host disease; prophylaxis, bone marrow transplantation, 736

Theophylline; cystic fibrosis; therapy, review, 657

Therapy Consultation, 479, 560
Dimethyl sulfoxide for treating anthracycline extravasation, 560
Increasing breast milk supply, 479

Thiazides
hypertension; systolic, therapy, geriatrics, review, 347
photosensitivity; adverse reactions, review, 580
toxicity; pancreatitis, review, 440

Thromboembolism; warfarin; prophylaxis, DUE criteria, 307

Thrombolytic agents; cerebrovascular disorders; therapy, review, 359

Thrombophlebitis; heparins; low-molecular-weight vs. unfractionated, 892

Thrombosis; enoxaparin; prophylaxis, FDA approvals, 471

Thyroid drugs; levothyroxine sodium; hypothyroidism therapy, 774

Ticlopidine hydrochloride; toxicity; cholestasis, 398

Ticlopidine; use; evaluation, criteria, 64

Tinzaparin; thrombophlebitis; low-molecular-weight heparins vs. unfractionated, 892

Tobramycin sulfate; body distribution; pharmacokinetics, septic shock, 131

Tobramycin; pharmacokinetics; prediction, vancomycin pharmacokinetics, 909

Toxicity
see also **Drugs, adverse reactions**
aldesleukin; DUE criteria, 853
amiodarone; thyroid dysfunction, therapy, 774
amiodipine besylate; side effects, 93
anthracyclines; extravasation, dimethyl sulfoxide therapy, 560
antiarrhythmic agents; side effects, 721
anti-inflammatory agents; nonsteroidal, DUE criteria, 780
antineoplastic agents; anemia, epoetin alfa therapy, DUE criteria, 925
asparaginase; pancreatitis, review, 440
atovaquone; side effects, 175; side effects, *P. carinii* pneumonia therapy, review, 563
azathioprine; pancreatitis, review, 440
benzodiazepines; flumazenil-use criteria, 536; overdose, flumazenil therapy, overview, 691; overdose, flumazenil therapy, review, 641; respiratory depression, flumazenil therapy, 483
cefexime; diarrhea, metronidazole therapy, 881
chloral hydrate; carcinogenicity, lack, 876
ciprofloxacin; DUE criteria, 226
cisapride, 876
cladribine, 391; side effects, leukemia therapy, review, 805
clonidine hydrochloride; side effects, lack, lactation, infants, 178
cyclosporine; DUE criteria, transplant recipients, 696
didanosine; pancreatitis, review, 440
didanosine, comparison, zalcitabine; side effects, AIDS therapy, NIAID clinical studies, 391
dietary supplements; excessive proteins, 900
diphtheria and tetanus toxoids and pertussis vaccines, combination, *Haemophilus b* oligosaccharide conjugate vaccines; FDA approvals, marketing, 391
drugs; photosensitivity, review, 580
enalapril maleate, comparison, hydrochlorothiazide,

propranolol hydrochloride; effects, cognition and motor activity, quality of life, 300

enoxaparin, 471

epoetin alfa; DUE criteria, 925

estrogens; pancreatitis, review, 440

felbamate; side effects, 713

felodipine; side effects, hypertension therapy, review, 261

fentanyl; inappropriate dosage recommendations, manufacturer, 718

finasteride; side effects, prostatic hypertrophy therapy, review, 15

floresquinan; high dose, increased mortality, clinical studies, 474; side effects, product withdrawal, 713

flumazenil; DUE criteria, 536; review, 641

furosemide; pancreatitis, review, 440

gallium nitrate; hypercalcemia therapy, malignancy-induced, review, 117

glycerin; enemas vs. suppositories, neonates, 846

heparins; low-molecular-weight vs. unfractionated, side effects, 892

hydrochlorothiazide, comparison, enalapril maleate, propranolol hydrochloride; effects, cognition and motor activity, quality of life, 300

indomethacin; injections, DUE criteria, neonates, 232

injections; extravasation, prediction, i.v. pressure, infants, 216

isradipine; side effects, hypertension therapy, review, 261

itraconazole; side effects, 6

lidocaine hydrochloride; monitoring, pharmacists' role, 527

lithium; DUE criteria, 617

lofloxacin; DUE criteria, 452

loratadine, 474

medroxyprogesterone acetate; side effects, 92

meperidine hydrochloride; patient-controlled analgesia, DUE criteria, 150

mercaptopurine; pancreatitis, review, 440

mesalamine, 555

methotrexate; side effects, asthma therapy, overview, 762

molgramostim; side effects, bone marrow transplantation, 520

morphine sulfate; patient-controlled analgesia, DUE criteria, 150

muromonab-CD3; encephalopathy, graft rejection therapy, 610

nebacumab; clinical studies, marketing, withdrawal, 254

nifedipine; bezoars, sustained-action tablets, 849

nutrition; parenteral, total, sodium disorders, 138

ofloxacin; DUE criteria, 452

paclitaxel; side effects, refractory ovarian neoplasms therapy, review, 401

pamidronate disodium; hypercalcemia therapy, malignancy-induced, review, 117

pentamidine; pancreatitis, review, 440

procainamide hydrochloride; side effects, lack, pregnancy, 58

propofol; aggressive sex behavior, 449

propranolol hydrochloride, comparison, enalapril maleate, hydrochlorothiazide; effects, cognition and motor activity, quality of life, 300

quinacrine hydrochloride; side effects, pleurodesis solutions, 693

replacement solutions; review, 335

sertraline hydrochloride; interactions, tranlycypromine, serotonergic syndrome, 222

sotalol hydrochloride; side effects, 883; side effects, 176

strontium chloride Sr 89, 632

sulfasalazine; agranulocytosis, sargramostim therapy, 179

sulfonamides; pancreatitis, review, 440

sulindac; pancreatitis, review, 440

tacrine hydrochloride, 873

teniposide; side effects, 6

tetracyclines; pancreatitis, review, 440

thiazides; pancreatitis, review, 440

ticlopidine; DUE criteria, 64

ticlopidine hydrochloride; cholestasis, 398

tranlycypromine sulfate; interactions, sertraline, serotonergic syndrome, 222

valproic acid; pancreatitis, review, 440

warfarin; DUE criteria, 307

zalcitabine, comparison, didanosine; side effects, AIDS therapy, NIAID clinical studies, 391

zolpidem tartrate; insomnia therapy, review, 814

Tranquilizers; haloperidol lactate; aggressive sex behavior therapy, propofol toxicity, 449

Transfection; gene therapy; research, review, 488

Transplantation
bone marrow; homologous, graft vs. host disease, prophylaxis, 736; molgramostim toxicity, 520
organs; cyclosporine, DUE criteria, 696

Tranlycypromine sulfate; interactions; sertraline, serotonergic syndrome, 222

Trauma; replacement solutions; head, resuscitation, clinical studies, review, 415

Tuberculosis; Interscience Conference on Antimicrobial Agents and Chemotherapy; surveillance programs, health professions, immunization, 167

Tumor necrosis factor- α inhibitors; shock; septic, therapy, review, 829

U

Ulcers
amoxicillin; peptic, *H. pylori*, combined therapy, review, 34
bismuth; peptic, *H. pylori*, combined therapy, review, 34
metronidazole; peptic, *H. pylori*, combined therapy, review, 34
tetracycline; peptic, *H. pylori*, combined therapy, review, 34

United States Public Health Service; Advisory Committee on Immunization Practices; protocols, vaccines, immune globulin, altered immunocompetence, 675

Urinary tract infections
ciprofloxacin; therapy, DUE criteria, 226
lofloxacin; therapy, DUE criteria, 452
ofloxacin; therapy, DUE criteria, 452

V

Vaccines
BCG; immunization, tuberculosis, surveillance programs, 167
diphtheria and tetanus toxoids and pertussis vaccines, combination, *Haemophilus b* oligosaccharide conjugate vaccines; FDA approvals, marketing, 391
Haemophilus b polysaccharide conjugate; low immunogenicity, list, 176
immunization; altered immunocompetence, ACIP protocols, 675

Valproic acid; toxicity; pancreatitis, review, 440

Vancomycin; pharmacokinetics; geriatrics, 481; prediction, aminoglycoside pharmacokinetics, 909

Vancomycin hydrochloride
dosage; calculations, computers, 126
pharmacokinetics; dosage, hematologic malignancy, 515

Vitamin A; mechanism of action; immunomodulating effects, review, 506

Vitamins
and minerals; dietary supplements, athletes, ergogenic effects, 900
supplements; cystic fibrosis therapy, review, 657
vitamin A; mechanism of action, immunomodulating effects, review, 506

Volume of distribution, see **Drugs, body distribution**

W

Warfarin
atrial fibrillation; therapy, 721
myocardial infarction; therapy, 197
use; evaluation, criteria, 307

Warfarin anticoagulants; warfarin; DUE criteria, 307

Weight; patients; effects, heparin dosage estimation, 597

Women; clinical studies; gender-related differences, FDA regulations, 395; new drugs, FDA regulations, 712

Writing; review; drugs, articles, 306

Z

Zalcitabine; comparison, didanosine; AIDS therapy, efficacy, NIAID clinical studies, 391

Zolimomab aritox; graft vs. host disease; prophylaxis, bone marrow transplantation, 736

Zolpidem tartrate; insomnia; therapy, review, 814

Author Index

A

- Adamson, Robert T. Book review, 864
 Adir, Joseph S. see Oparaoji, Edward C., 131
 Alaniz, Cesar Pharmacologic management of adult idiopathic nephrotic syndrome, 429
 Allen, Jill E. Drug-induced photosensitivity, 580
 Allen, Nancy M. Procainamide administration during pregnancy, 58
 Alsop, Judith Book review, 627
 Anderson, John R. see Zeisler, John A. Jr., 527
 Anderson, Philip O. Increasing breast milk supply (Therapy Consultation), 479
 Andersson, Borje S. see Ippoliti, Cindy, 520
 Annett, Miriam P. see McCorvey, Eddie Jr., 300
 Artymowicz, Richard J. Atovaquone: a new antipneumocystis agent, 563
 Ateshkadi, Arash *Helicobacter pylori* and peptic ulcer disease, 34
 Ateshkadi, Arash see also Bohenek, Wayne S., 602

B

- Baltz, Julie K. Cladribine for the treatment of hematologic malignancies, 805
 Bandettini, Francis C. see Bhatara, Vinod S., 222
 Barron, Richard L. Criteria for use of aldesleukin in adults, 853
 Barron, Richard L. Pathophysiology of septic shock and implications for therapy, 829
 Bashaw, E. Dennis see Hale, Victoria G., 255
 Bastide, Pierre see Chopineau, Jean, 770
 Bazin, Jean-Etienne see Chopineau, Jean, 770
 Bedikian, Annet see Okamoto, Mark P., 134
 Beltz, Susan Durdan Efficacy of nutritional supplements used by athletes, 900
 Bennett, Teresa A. Criteria for use of epoetin alfa in adult cancer and orthopedic-surgery patients, 925
 Berchou, Richard C. Book review, 242, 467
 Berne, Thomas V. see Okamoto, Mark P., 134
 Bhatara, Vinod S. Possible interaction between serotonin and tranlycypromine, 222
 Binkley, Jeffrey F. Effects of human albumin administration on visceral protein markers in patients receiving parenteral nutrition, 377
 Blanchard, Nick Book review, 787
 Bloom, Elana J. see Schwinghammer, Terry L., 736
 Bobo, Don Jr. see Phelps, Stephanie J., 216
 Boehm, Kristi A. see Christensen, Michael L., 606
 Boh, Larry E. see Lestico, Mitchell R., 571
 Bohenek, Wayne S. Effect of peritonitis on plasma and dialysate α_2 -acid glycoprotein concentrations in peritoneal dialysis patients, 602
 Borchardt-Phelps, Pamela K. Book review, 76
 Bottorff, Michael see Joch, Lois E., 597
 Brosius, Frank C. III see Alaniz, Cesar, 429
 Brown, Rex O. see Binkley, Jeffrey F., 377
 Brown, Rex O. see also Mowatt-Larssen, Christine A., 276
 Bunjes, R. Clonidine and breast-feeding (letter), 178
 Burr, J. Michael see Renfro, William H., 232

C

- Caballero, Dolores see Fernández de Gatta, María del Mar, 515
 Calis, Karim Anton see Goldspiel, Barry R., 488
 Canaday, Bruce R. Amorous, disinhibited behavior associated with propofol, 449
 Cannon, Miriam A. see Povlow, Matthew J., 13
 Cantril, Kimberley A. see Jungnickel, Paul W., 257
 Cantú, Thomas G. see Goemann, Marti, 802
 Carter, Barry L. Current recommendations of the joint national high blood pressure committee, 53
 Carter, Barry L. see also Furnaga, Elaine M., 347
 Centers for Disease Control and Prevention Recommendations of the Advisory Committee on Immunization Practices (ACIP): Use of vaccines and immune globulins for persons with altered immunocompetence, 675
 Champlin, Richard E. see Ippoliti, Cindy, 520
 Chan, Frances A. see Sargent, Andrea L., 613
 Chandler, Mary H. H. see Rhoney, Denise H., 913
 Chandler, Mary H. H. see also Tsubaki, Tsuneo, 685
 Chandler, Mary H. H. see also Welch, Laura P., 909

- Cheong, Ronnie Lum see Oparaoji, Edward C., 131
 Chin, Alfred see Okamoto, Mark P., 134
 Chopineau, Jean Assay for midazolam in liquor folliculi during in vitro fertilization under anesthesia, 770
 Chow, Moses S. S. see Fan, Chengde, 917
 Chow, Moses see also Kertland, Heather, 244
 Christensen, Michael L. Clearance of *N*-acetyl-t-tyrosine in infants receiving a pediatric amino acid solution, 606
 Cookson, Thomas L. see Ito, Matthew K., 126
 Cornish, Laura A. see Shaheen, Barbara E., 588
 Cornwell, Edward E. III see Oparaoji, Edward C., 131
 Côté, Daniel Dosage of transdermal fentanyl (letter), 718
 Culbert, James P. see McCorvey, Eddie Jr., 300
 Czizaky, Mark J. Low-molecular-weight heparins for the treatment of deep-vein thrombosis, 892

D

- D'Amato, Steven see Fraser, Gilles L., 481
 D'Amelio, Louis F. see Wagner, Bertil K. J., 335, 415
 Danziger, Larry H. Prophylaxis with aztreonam plus metronidazole during appendectomy (letter), 803
 Davis, Sharon K. see Nanno, Mark A., 696
 Deamer, Robert L. Temafloxacin-induced hemolytic anemia and renal failure, 380
 Deisseroth, Albert B. see Ippoliti, Cindy, 520
 DeLisa, Anne F. see Gregory, R. Elizabeth, 398
 Deppe, Scott A. see Sargent, Andrea L., 613
 DeVito, Joseph M. Bioequivalence of oral and injectable levoleucovorin and leucovorin, 293
 DiPiro, Joseph T. Book review, 933
 Doering, Paul L. see Beltz, Susan Durden, 900
 Dole, Ernest J. Book review, 704
 Dominguez-Gil Huriel, Alfonso see Fernández de Gatta, María del Mar, 515
 Donnelly, Andrew J. Book review, 241
 Dreyfus-Vigil, Susan D. see Ito, Matthew K., 126
 Duc, Thomas A. see Michael, Katherine A., 150
 Duren, Lars L. see Ito, Matthew K., 126

E

- Engel, Lisa M. see Rospond, Raylene M., 560
 Englander, Frank A. see Shalansky, Stephen J., 483
 Ezell, Jeanne R. see Marken, Patricia A., 617

F

- Fallo, Sally A. see Min, David I., 610
 Fan, Chengde Accuracy of unbound-quinidine concentration determination after ultrafiltration, 917
 Fernández de Gatta, María del Mar Vancomycin pharmacokinetics and dosage requirements in hematologic malignancies, 515
 Fox, A. W. Use and safety of sumatriptan (letter), 258
 Fraser, Gilles L. Vancomycin pharmacokinetics in elderly patients (letter), 481
 Frisalone, Julie Criteria for use of intravenous ciprofloxacin for infections in adult patients, 726
 Fruns, Ignacio see Fernández de Gatta, María del Mar, 515
 Frye, Carla B. see Underwood, Theodore W., 440
 Furnaga, Elaine M. Isolated systolic hypertension in older patients, 347

G

- Gales, Barry J. see Gales, Mark A., 881
 Gales, Mark A. Recognition of severe cefixime-induced diarrhea (letter), 881
 Garnett, William R. Book review, 387
 Geraets, Douglas R. Atrial fibrillation and atrial flutter, 721
 Gill, Mark A. see Okamoto, Mark P., 134
 Giralt, Sergio see Ippoliti, Cindy, 520
 Glowacki, Robert C. see Rospond, Raylene M., 179
 Goemann, Marti Ketoconazole and gastric acidity (letter), 802
 Goldspiel, Barry R. Human gene therapy, 488
 Good, Chester B. Criteria for long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) in adult inpatients and outpatients, 780
 Goodin, Susan see Tsubaki, Tsuneo, 685
 Gray, Thomas M. Gentamicin pharmacokinetics in term

- newborn twins, 615
 Greaney, James J. Jr. Ticlopidine-induced cholestatic jaundice (letter), 398
 Green, Laurence see Goldspiel, Barry R., 488
 Gregory, R. Elizabeth Pacitaxel: a new antineoplastic agent for refractory ovarian cancer, 401

H

- Hale, Victoria G. Pharmacokinetics of oxaprozin (letter), 255
 Hall, Maura see Wallace, Carla S., 657
 Hall, Thomas G. Update on the medical treatment of hypercalcemia of malignancy, 117
 Hekmat, Elham see Oparaoji, Edward C., 131
 Helms, Richard A. see Christensen, Michael L., 606
 Heming, Deborah see Deamer, Robert L., 380
 Hernández, Jesús M. see Fernández de Gatta, María del Mar, 515
 Hess, David A. see Greaney, James J. Jr., 398
 Hiatt, Janet Criteria for use of warfarin in adult inpatients and outpatients, 307
 Hoehns, James D. Zolpidem: a nonbenzodiazepine hypnotic for treatment of insomnia, 814
 Hoffman, Elyse J. Flumazenil: a benzodiazepine antagonist, 641
 Holzinger, D. see Bunjes, R., 178
 Hruska, Barbara M. see Good, Chester B., 780
 Hsu, Van Doren Criteria for use of ticlopidine in adult inpatients and outpatients, 64
 Hsu, Van Doren Use and safety of sumatriptan (letter), 258

I

- Ippoliti, Cindy Adverse effects of molgramostim in marrow transplant recipients, 520
 Ito, Matthew K. Computer dosing program for the initiation of vancomycin therapy, 126

J

- Jaffe, Craig A. see Khanderia, Ujjaini, 774
 James, Robert E. III see Deamer, Robert L., 380
 James, Vivien E. see Artymowicz, Richard J., 563
 Janny, Laurent see Chopineau, Jean, 770
 Joch, Lois E. Accuracy of a first-order model for estimating initial heparin dosage, 597
 Johnson, Curtis A. see Ateshkadi, Arash, 34
 Johnson, Curtis A. see also Bohenek, Wayne S., 602
 Johnson, Jerry B. see DeVito, Joseph M., 293
 Johnston, Philip E. Book review, 704
 Jungnickel, Paul W. Relative safety and efficacy of pravastatin (letter), 257

K

- Karnack, Charles M. Book review, 933
 Kaslovsky, Robert A. see Lomaestro, Ben M., 693
 Kawaguchi, Yoshihiro see Ueno, Kazuyuki, 768
 Kertland, Heather Self-study materials review, 244
 Kessler, David A. MEDWatch: the new FDA medical products reporting program, 529
 Kessler, John M. Book review, 934
 Khanderia, Ujjaini Amiodarone-induced thyroid dysfunction, 774
 Kienzie, Michael G. see Geraets, Douglas R., 721
 Kimelblatt, Bruce J. see Klausner, Mark A., 718
 Klausner, Mark A. Dosage of transdermal fentanyl (letter), 718
 Knupp, Catherine A. see Okamoto, Mark P., 134
 Koenker, Nancy see Deamer, Robert L., 380
 Koepf, Robin M. see Zenk, Karin E., 846
 Kozloski, Gary D. see DeVito, Joseph M., 293
 Krenzlok, Edward P. Judicious use of flumazenil (editorial), 691
 Kudsk, Kenneth A. see Binkley, Jeffrey F., 377
 Kuhn, Robert J. see Wallace, Carla S., 657

L

- Labreche, Dusan G. Book review, 706
 Lam, Nancy P. see Ateshkadi, Arash, 34
 Lam, Y. W. Francis Fluorescence polarization immuno-

Annual Index

- assay of quinidine, procainamide, and *N*-acetylprocainamide using Cobas-FP reagents, 49
- Lanao, José Martínez see Fernández de Gatta, María del Mar, 515
- Leader, W. Greg see Rhoney, Denise H., 913
- Leader, W. Greg see also Tsubaki, Tsuneo, 685
- Lesar, Timothy S. see Lomaestro, Ben M., 693
- Lestico, Mitchell R. Polymyalgia rheumatica, 571
- Leviton, Ira M. see Frisolone, Julie, 226
- Lewis, Kelly S. see Michael, Katherine A., 150
- Liem, Lorraine A. see Zenk, Karin E., 846
- Lomaestro, Ben M. Pleurodesis with solution prepared from quinine hydrochloride tablets, 693
- Lugo, Ralph A. Pathogenesis and treatment of bronchiolitis, 95
- Lutonski, Dave M. see Joch, Lois E., 597

M

- Mahoney, Charles D. see Greaney, James J., Jr., 398
- Maiese, Susan see Ippoliti, Cindy, 520
- Mailliard, James A. see Rospond, Raylene M., 179
- Maloley, Pierre A. see Jungnickel, Paul W., 257
- Manzo, John see Frisolone, Julie, 226
- Marken, Patricia A. Criteria for use of lithium in adult inpatients and outpatients, 617
- McCorvey, Eddie Jr. Book review, 867
- McCorvey, Eddie Jr. Effect of hydrochlorothiazide, enalapril, and propranolol on quality of life and cognitive and motor function in hypertensive patients, 300
- McKenney, James M. see McCorvey, Eddie Jr., 300
- Meister, Fred L. see Zeisler, John A., 527
- Michael, Katherine A. Criteria for use of patient-controlled analgesia in adults, 150
- Miller, Jane L. Conference, reports address public-health implications of tuberculosis (News), 167
- Miller, Jane L. Reviews of new drugs (editorial), 306
- Miller, Lucinda G. Pharmacokinetics of oxaprozin (letter), 256
- Min, David I. Encephalopathy associated with muremonab-CD3, 610
- Mirtallo, Jay M. see Sunycz, Lisa, 138
- Moline, Margaret L. Pharmacologic strategies for managing premenstrual syndrome, 181
- Montello, Michael J. see Baltz, Julie K., 805
- Mowatt-Larsen, Christine A. Specialized nutritional support in respiratory disease, 276
- Murphy, Christine M. see Furgam, Elaine M., 347
- Murray, Michael D. Book review, 866

N

- Nahata, Milap C. see Lugo, Ralph A., 95
- Nakahiro, Randall K. see Okamoto, Mark P., 134
- Naumann, Terry N. see Shalansky, Stephen J., 483
- Ninno, Mark A. Criteria for use of cyclosporine in adult transplant recipients, 696

O

- Okamoto, Mark P. Cefepime pharmacokinetics in patients with acute cholecystitis undergoing cholecystectomy, 134
- Oparaoji, Edward C. Aminoglycoside volume of distribution in postoperative patients with septic shock, 131
- Orlando, Patricia L. Book review, 82
- Oxton, Lisa L. see Bohenek, Wayne S., 602

P

- Page, Richard L. see Allen, Nancy M., 58
- Palmieri, James see Alaniz, Cesar, 429
- Perry, Paul J. see Hoehns, James D., 814
- Phelps, Stephanie J. Infusion technology for predicting and detecting infiltration of peripheral intravenous catheter sites in infants, 216

- Pickworth, Kerry K. Long-term dobutamine therapy (letter), 13
- Poe, Timothy E. see Fox, A. W., 258
- Povlov, Matthew J. Long-term dobutamine therapy (letter), 13
- Powers, Douglas A. see Binkley, Jeffrey F., 377
- Prichard, John G. see Deamer, Robert L., 380
- Proctor, Jack D. see McCorvey, Eddie Jr., 300
- Przeplorka, Donna see Ippoliti, Cindy, 520

R

- Raebel, Marsha A. Self-study material review, 548
- Rawlings, D. Jim see Renfro, William H., 232
- Reid, Dana J. Methotrexate for the treatment of chronic corticosteroid-dependent asthma, 762
- Renfro, William H. Criteria for use of indomethacin injection in neonates, 232
- Rhoney, Denise H. Modified Michaelis-Menten equation for estimating unbound-phenytoin concentrations, 913
- Rogers, Susan J. Book review, 707
- Rogers, Susan J. Pathophysiology and treatment of acute ischemic stroke, 359
- Rospond, Raylene M. Dimethyl sulfoxide for treating anthracycline extravasation (Therapy Consultation), 560
- Rospond, Raylene M. Sargramostim for sulfasalazine-induced agranulocytosis (letter), 179
- Rumore, Martha M. Vitamin A as an immunomodulating agent, 506

S

- San Miguel, Jesús F. see Fernández de Gatta, María del Mar, 515
- Sargent, Andrea I. Seizure associated with ondansetron, 613
- Sautou, Valérie see Chopineau, Jean, 770
- Schaefer, C. see Bunjes, R., 178
- Schaff, Robyn A. Burns see Hall, Thomas G., 117
- Schoeffler, Pierre see Chopineau, Jean, 770
- Schumacher, Gerald E. Book review, 323
- Schuna, Arthur A. see Lestico, Mitchell R., 571
- Schwinghammer, Terry L. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation, 736
- Segars, Larry W. see Reid, Dana J., 762
- Shaheen, Barbara E. Magnesium in the treatment of acute myocardial infarction, 588
- Shalansky, Stephen J. Effect of flumazenil on benzodiazepine-induced respiratory depression, 483
- Shepherd, Michele F. Bezoar formed by fragments of extended-release nifedipine tablets, 849
- Shepherd, Michele F. Criteria for use of flumazenil in adult inpatients and outpatients, 536
- Sherman, David G. see Rogers, Susan J., 359
- Simonian, Jill S. see Ito, Matthew K., 126
- Siram, Suryanarayana see Oparaoji, Edward C., 131
- Skovseth, Jon R. see Zeisler, John A., Jr., 527
- Slimowitz, Richard Book review, 240, 864
- Smith, Steven P. Book review, 241
- Smith, Terry see Ippoliti, Cindy, 520
- Spinler, Sarah A. see Czizak, Mark J., 892
- Spivey, J. Michael Criteria for use of ofloxacin and lomefloxacin in adult inpatients and outpatients, 452
- Sproat, Thomas T. see Yedinak, Kimberly C., 197
- Steiner, Joseph F. Finasteride: a 5 α -reductase inhibitor, 15
- Storm, Michael C. see Christensen, Michael L., 606
- Sunycz, Lisa Sodium imbalance in a patient receiving total parenteral nutrition, 138
- Symes, Laura R. see Walton, Ted, 261

T

- Taketomo, Carol K. Book review, 787
- Talley, C. Richard The new *AJHP* (editorial), 526
- Tanaka, Kazuhiko see Ueno, Kazuyuki, 768
- Terrisse, Marie-Pierre see Chopineau, Jean, 770

- Theisen, Virginia see Khandaria, Ujjaini, 774
- Tisdale, James E. see Fan, Chengde, 917
- Tobert, Jonathan A. Relative safety and efficacy of pravastatin (letter), 256
- Tolley, Elizabeth A. see Phelps, Stephanie J., 216
- Tonelli, Alfred P. see DeVito, Joseph M., 293
- Tsubaki, Tsuneo Estimation of creatinine clearance in patients with gynecologic cancer, 685

U

- Ueno, Kazuyuki Pharmacokinetics of mexiletine in middle-aged and elderly patients, 768
- Ujhelyi, Michael R. see Fan, Chengde, 917
- Umstead, Greg S. Self-study materials review, 243
- Underwood, Theodore W. Drug-induced pancreatitis, 440

V

- Valdés, Verónica see Anderson, Philip O., 479
- Valley, Amy W. see Barron, Richard L., 853
- Vaughan, Leigh M. Allergic bronchopulmonary aspergillosis, 24
- Veal, Donna F. see Christensen, Michael L., 606

W

- Wagner, Bertil K. J. Pharmacologic and clinical considerations in selecting crystalloid, colloidal, and oxygen-carrying resuscitation fluids, part 1, 335; part 2, 415
- Wallace, Carla S. Pharmacologic management of cystic fibrosis, 657
- Walton, Ted Felodipine and isradipine: New calcium-channel-blocking agents for the treatment of hypertension, 261
- Warren, Eric W. see Hoffman, Elyse J., 641
- Watkins, Cindy E. see Lam, Y. W. Francis, 49
- Welch, Laura P. Predicting vancomycin pharmacokinetics by using aminoglycoside pharmacokinetics, 909
- Wheeler, Terrie see Good, Chester B., 780
- Williams, Debra J. see Joch, Lois E., 597
- Wingert, June see Bennett, Teresa A., 925
- Witmer, David R. Comment on ASHP therapeutic guidelines (letter), 399
- Wittkowsky, Ann K. see Hiatt, Janet, 307
- Wojtylski, Stacey L. see Binkley, Jeffrey F., 377
- Wood, Warren A. Comment on ASHP therapeutic guidelines (letter), 399
- Wright, Jackson T. Jr. see McCorvey, Eddie Jr., 300

Y

- Yedinak, Kimberly C. Heparin and warfarin therapy after acute myocardial infarction, 197
- Yellin, Albert E. see Okamoto, Mark P., 134

Z

- Zanetti, Leslie A. Farquhar Sotalol: a new class III antiarrhythmic agent, 883
- Zeisler, John A. Jr. Lidocaine therapy: time for re-evaluation, 527
- Zellmer, William A. Context of a transition (editorial), 923
- Zenk, Karin E. Comparative efficacy of glycerin enemas and suppository chips in neonates, 846
- Zimmerman, Stephen W. see Bohenek, Wayne S., 602

Advertising Index

A

American Lung Association

Institutional, 558

American Society of Hospital Pharmacists

AHFS Drug Information 93, 94, 448, 525, 690

American Journal of Hospital Pharmacy, 828, 921

ASHP Membership, 177

ASHP Section of Home Care Practitioners, 882

Basic Skills in Interpreting Laboratory Data, 541, 609, 674

CiteSearch, 316

Clinical Pharmacokinetics Pocket Reference, 382, 400, 625, 635, 788, 862, 935

Clinical Pharmacy, 8, 149

Clinical Skills Program, Module 1: Reviewing Patient Medical Charts, 180, 275, 475, 587, 640, 779, 868, 891

Clinical Skills Program, Module 2: Building a Pharmacist's Data Base, 545, 559, 705, 784

Clinical Skills Program, Module 3: Constructing a Patient's Drug Therapy Problem List, 801, 880

Concepts in Immunology and Immunotherapeutics, 33

Concepts in Oncology Therapeutics, 14, 695

Criteria for Drug Use Evaluation: Volumes 1, 2, and 3, 73, 242, 616

Drug Information on CD, 540, 948

The Elements of Quality in Pharmaceutical Care, 125

George P. Provost Editorial Internship, 240

Guidelines for Administration of Intravenous Medications to Pediatric Patients, 137, 260, 543, 684, 803, 908

Handbook of Institutional Pharmacy Practice, 75

Handbook on Injectable Drugs and Supplement, 621

Handbook on Injectable Drugs, 7th Edition, 83

Home Infusion Software, 922

IPA Thesaurus, 399

IV-EASE, 317

Manual for Pharmacy Technicians, 459, 628

Medication Teaching Manual, 5th Edition, 547, 852

Medication Teaching Manual/MedTeach, 562, 714, 936

MedTeach, 259, 636

Pocket Guide to Injectable Drugs, 1993 Edition, 292, 514, 558, 788

Practical Aspects of Intravenous Drug Administration, 243, 428

QARx 3.0, 315

Supplement to the Handbook on Injectable Drugs, 708

Understanding Medical Terms: A Guide for Pharmacy Practice, 70

Amgen Inc.

Epogen, 4-5, 162-163, 168-169, 248-249, 332-333, 396-397, 472-473, 556-557, 638-639, 716-717, 798-799, 874-875

Neupogen, 77-80, 87-90, 319-322

ASHP Research and Education Foundation

Anticoagulation Clinic Traineeship Program, 482

Fellowships, 865

Asthma & Allergy Foundation of America

Institutional, 334

B

Burroughs Wellcome Company

Exosurf Neonatal, 9-12

C

CARE

Institutional, 82

Cook County Hospital

Positions Available, 715

Creighton University

Positions Available, 475

E

Egleston Children's Hospital

Position Available, 628

Eisenhower Medical Center

Position Available, 258

G

Good Samaritan Regional Medical Center

Position Available, 480

Greater Baltimore Medical Center

Position Available, 175

H

Harwood Academic Publishers

Journal of Applied Therapeutics, 334

The Hebrew University of Jerusalem

Position Available, 317

L

Lederle Laboratories, A Division of American

Cyanamid Company

Institutional, 631, 711, 804

M

Micromedex, Inc.

Positions Available, 84, 239, 879

N

National Council on Patient Information and

Education

Institutional, 706, 794

National Easter Seal Society

Institutional, 254

O

Ohio State University

Position Available, 164

P

PCS Health Systems, Inc.

Positions Available, 317, 334, 467

Pharmakon International, Inc.

Position Available, 384

Q

The Queen's Medical Center

Position Available, 467

R

Roche Laboratories, A Division of

Hoffmann-La Roche Inc.

Rocaphin, Feb IBC, OBC, Apr IBC, OBC, Jun IBC, OBC, Aug IBC, OBC, Oct IBC, OBC, Dec IBC, OBC

Romazicon, 791-792, 877-878

S

St. Jude Children's Research Hospital

Institutional, 480

SmithKline Beecham

Timentin, Jan IBC, OBC, Mar IBC, OBC, May IBC, OBC, Jul IBC, OBC, Sep IBC, OBC, Nov IBC, OBC

T

Third International Symposium on Oncology

Pharmacy Practice

Symposium, 81

W

Wyeth-Ayerst Laboratories

Ativan Injection, 158-160, 172-174, 250-252, 328-330, 392-394, 476-478, 552-554, 633-634, 719-720, 795-796, 871-872

Tubex, Jan IFC, Feb IFC, Mar IFC, Apr IFC, May IFC, Jun IFC, Jul IFC, Aug IFC, Sep IFC, Oct IFC, Nov IFC, Dec IFC